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Summary 
A significant fraction of inherited monogenic disorders are caused by patient-specific 
mutations dispersed over the entire locus of the affected gene. Although correcting 
these mutations by introducing healthy gene copies into the genome of the diseased 
cells proved effective in several clinical gene therapy trials and with more advanced 
vectors safety and efficacy could be improved, insertional mutagenesis and 
unregulated expression of genes deprived of their endogenous control elements 
remains a concern when using randomly integrating vectors. As has been shown 
repeatedly in clinical trials random vector insertions are susceptible to epigenetic 
silencing and can cause cancer by the activation of adjacent proto-oncogenes.  
 
The development of genome editing tools capable of modifying any prespecified 
genomic sequence with unprecedented accuracy opened up a wide range of new 
possibilities in gene manipulation including targeted gene repair. In particular, 
CRISPR/Cas9 system, a prokaryotic adaptive immune system and its swift 
repurposing for genome editing was widely adopted as the hitherto simplest genome 
editing tool. In combination with a single guide RNA (sgRNA) the Cas9 endonuclease 
generates DNA double strand breaks (DSBs) at prespecified genomic loci that are 
repaired either by homology directed repair (HDR) or nonhomologous end joining 
(NHEJ).  
 
Correction of human disease mutations by this technology has been thus far largely 
based on homologous recombination requiring an exogenous donor template along 
with RNA guided (gRNA) Cas9 endonucleases (RGNs). In most applications, RGNs 
and templates were delivered to the diseased cells by electroporation of several 
plasmids each expressing one of the functional components needed for targeted gene 
modification. However, transducing the functional components required for homology 
directed repair (HDR) on different plasmids and considering that electroporation is 
quite harmful to the target cells, only a small fraction of the cells survive transfection 
and even fewer retain all functional components. As a result, the number of gene 
corrected cells is usually quite low and reduced even further by the inherent bias of the 
cell's double strand break (DSB) machinery towards NHEJ.  
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This thesis explores the efficiency of gene repair by NHEJ in hematopoietic cells 
harboring patient specific point mutations in the Cytochrome b-245 heavy chain gene 
(CYBB) whose inactivation causes chronic granulomatous disease (X-CGD), - a life-
threatening immunodeficiency disorder. Although in contrast to HDR, NHEJ is error 
prone, the present work was based on the theoretical assumption that about, one-third 
of the insertions/deletions (indels) associated with NHEJ should restore the open 
reading frame (ORF) disrupted by a particular disease mutation. This would lead to a 
significant number of ORF reconstitutions of which some, depending on the position 
and type of the original mutation, should either completely or partially recover protein 
function. Moreover, donor template free delivery of RGNs on one rather than multiple 
expression vectors by lentiviral infection was expected to improve gene repair 
efficiencies and to reduce toxicity of gene transduction.  
 
In initial experiments designed to determine the efficiency of gene repair by NHEJ 32D 
hematopoietic cells expressing four different EGFP reporter transgenes harboring N-
terminal frameshift mutations were nucleofected each with Cas9 and corresponding 
sgRNAs. Consistent with previous genome editing protocols involving transfection, 
gene repair efficiency was low, ranging from 2.3% to 5.5%.  
 
Similar testing was performed in human PLB-985 leukemia cells expressing one copy 
of a mutationally inactivated EGFP reporter (mEGFP). However, to increase 
transduction rates and ensure transient RGN expression, the RGNs were delivered by 
integration defective lentiviruses (IDLVs). Unlike transfection IDLV delivery of RGNs 
yielded high on-target mutation rates leading to mEGFP repair rates of up to 27%. 
Collectively, the results demonstrate that mEGFP repair efficiency improved by one 
order of magnitude after changing the RGN delivery protocol from plasmid 
nucleofection to IDLV infection. 
 
This strategy was tested further in PLB cells harboring bona fide disease mutations. 
For this, four X-CGD-patient specific CYBB mutations including two frameshift, one 
nonsense and one missense mutation were individually transduced into CYBB null 
PLB cells (XCGD-PLB). While subsequent delivery of the corresponding RGNs 
effectively repaired the frameshift mutations in up to 10% of the treated cells, the repair 
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efficiency of the nonsense and missense mutations was with less than 2% rather 
ineffective.  
 
As about 20 - 25% of most inherited blood disorders are caused by frameshift 
mutations, the results of this thesis suggest that up to a quarter of all patients suffering 
from monogenic blood disorders could benefit from a gene therapy employing 
personalized, donor-template free RGNs. 
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Zusammenfassung 
Ein signifikanter Anteil hereditärer, monogenetischer Erkrankungen wird durch 
patientenspezifische Mutationen verursacht, die über den gesamten Locus des 
betroffenen Gens verteilt sind. Obwohl sich in mehreren klinischen Studien die 
Korrektur dieser Mutationen durch die Einführung gesunder Genkopien in das Genom 
der erkrankten Zellen bewährt hat und mit fortschrittlicheren Vektoren die Sicherheit 
und Wirksamkeit verbessert werden kann, bleibt die Insertionsmutagenese und die 
unregulierte Expression von Genen außerhalb des Einflusses ihrer endogenen 
Kontrollelemente ein Problem bei der Verwendung von zufällig integrierenden 
Vektoren. Wie in klinischen Studien wiederholt gezeigt wurde, sind diese Vektoren 
anfällig für epigenetisches Silencing (Gen-Stilllegung) und können durch Aktivierung 
benachbarter Protoonkogene Krebs verursachen. 
 
Die Entwicklung von Genom-Editierungs-Technologien, die in der Lage sind, jede 
vorher festgelegte genomische Sequenz mit bisher unerreichter Präzision zu 
modifizieren, eröffnete eine breite Palette neuer Möglichkeiten in der Genmanipulation 
einschließlich gezielter Genreparatur. Insbesondere das prokaryotische adaptive 
Immunsystem CRISPR/Cas9, fand nach seiner eleganten Umfunktionierung zur 
Editierung doppelsträngiger DNA wurde als das bisher einfachste Genom-
Editierwerkzeug breite Akzeptanz in der wissenschaftlichen Gemeinschaft. 
In Kombination mit einer einzigen guide RNA (sgRNA) erzeugt die Cas9-
Endonuklease DNA-Doppelstrangbrüche (DSBs) an vordefinierten genomischen Loci. 
Diese DSB können entweder durch Homologie-gerichtete Reparatur (HDR) oder nicht-
homologe Verbindung der Strangenden (NHEJ) repariert werden. 
 
Die Korrektur menschlicher Krankheitsmutationen durch diese Technologie basierte 
bislang weitgehend auf Homologie-gerichtete Reparatur, die neben RNA-geführten 
(gRNA) Cas9-Endonukleasen (RGNs) eine exogene homologe Donor-Matrize 
erfordert. In den meisten Anwendungen wurden RGNs und Matrizen durch 
Elektroporation in die erkrankten Zellen eingebracht, die auf mehreren Plasmiden 
kodiert sind, welche jeweils eine der funktionellen Komponenten exprimiert, die für eine 
gezielte Genmodifikation benötigt werden. Aufgrund dessen, dass die für die 
Homologie-gerichtete Reparatur (HDR) erforderlichen Komponenten auf 
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verschiedenen Plasmiden liegen und die Elektroporation für die Zielzellen ziemlich 
schädlich ist, überlebt nur ein kleiner Teil der Zellen die Transfektion und noch weniger 
beinhalten alle funktionellen Komponenten für die HDR. Infolgedessen ist die Anzahl 
genkorrigierter Zellen in der Regel recht niedrig und wird durch die inhärente 
Bevorzugung von NHEJ seitens der Doppelstrangbruch-Maschinerie in Stammzellen 
noch weiter reduziert. 
 
In dieser Arbeit wird die Effizienz der Genreparatur durch NHEJ in hämatopoetischen 
Zellen mit patientenspezifischen Punktmutationen im Cytochrom b-245-Gen (CYBB) 
untersucht, dessen Inaktivierung die lebensbedrohliche Immunschwächekrankheit 
chronische Granulomatose (X-CGD) verursacht. Obwohl die NHEJ im Gegensatz zu 
HDR fehleranfällig ist, basierte die vorliegende Arbeit auf der theoretischen Annahme, 
dass ungefähr ein Drittel der mit NHEJ assoziierten Insertionen/Deletionen (Indels) 
den korrekten Leserahmen (ORF) wiederherstellen werden, der initial durch eine 
bestimmte Krankheitsmutation verschoben war. Dies würde zu einer signifikanten 
Anzahl von ORF-Rekonstitutionen führen, von denen einige, abhängig von der 
Position und Art der ursprünglichen Mutation, entweder die Proteinfunktion vollständig 
oder teilweise wiederherstellen sollten. Darüber hinaus wurde erwartet, dass die 
Donor-Matrize-freie Abgabe von RGNs auf einem statt von mehreren 
Expressionsvektoren durch lentivirale Infektion die Effizienz der Genreparatur 
verbessern und die Toxizität der Gentransduktion verringert. 
 
Beim ersten Experimenten zur Bestimmung der Effizienz der Genreparatur durch 
NHEJ wurden die 32D hämatopoetische Zellen, die vier verschiedene EGFP-
Reportertransgene mit N-terminalen Frameshift-Mutationen exprimierten, jeweils mit 
Cas9 und entsprechenden sgRNAs nukleofektiert. In Übereinstimmung mit früheren 
Genom-Editierprotokollen, die eine Transfektion beinhalten, war die Effizienz der Gen-
Reparatur gering und lag zwischen 2,3% und 5,5%.  
 
Ähnliche Tests wurden in humanen PLB-985 Leukämiezellen durchgeführt, die eine 
Kopie eines mutationsinaktivierten EGFP-Reporters (mEGFP) exprimierten. Um die 
Transduktionsraten zu erhöhen und transiente RGN-Expression zu gewährleisten, 
wurden die RGNs durch Integrations-defekte Lentiviren (IDLVs) transduziert. Im 
Gegensatz zur Nucleofektion ergab die IDLV-Infektion von RGNs eine hohe On-
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Target-Mutationsraten, was zu mEGFP-Reparaturraten von bis zu 27% führte. 
Insgesamt zeigen die Ergebnisse, dass sich die mEGFP-Reparatureffizienz um eine 
Größenordnung verbessert hat, nachdem das RGN Transduktionsprotokoll von 
Plasmid-Nukleofektion zu IDLV-Infektion geändert wurde. 
 
Anschließend wurde die Strategie bei der hereditären septischen Granulomatose (X-
CGD) die durch Mutationen im Cytochrome b-245 beta polypeptide (CYBB) Gen 
entstehen, in PLB985 Zellen getestet. Dazu wurden vier X-CGD-Patientenspezifische 
CYBB-Mutationen mit zwei Frameshift-, einer Nonsense- und einer Missense-Mutation 
einzeln in CYBB-Null-PLB-Zellen (XCGD-PLB) eingebracht. Während der 
nachfolgenden Transduktion der Zellen mit den entsprechenden IDLV-RGNs, wurden 
effektiv bis zu 10% die Frameshift-Mutationen korrigiert. Die Reparatureffizienz bei den 
Nonsense- und Missense-Mutationen war mit weniger als 2% jedoch eher ineffektiv. 
 
Da etwa 20 – 25% der meisten vererbten Bluterkrankungen durch Frameshift-
Mutationen verursacht werden, legen die Ergebnisse dieser Arbeit nahe, dass ein 
Viertel aller an monogenen Blutkrankheiten leidenden Patienten von einer Gentherapie 
profitieren könnten, die personalisierte, Donor-Template-freie RGNs verwendet. 
 
 
 
  Introduction 
7 
 
1. Introduction 
1.1 The hematopoietic system 
The first theory of hematopoiesis was postulated by A. Maximow in 1909, stating 
that hematopoiesis accounts for the livelong of formation of blood cells and plasma 
from hematopoietic stem cells (HSC)1. Healthy adults produce billions of blood cells 
each day to replace an equal number of senescent or apoptotic cells removed from 
circulation2,3. The HSC are ultimately responsible for blood cell renewal during which 
they differentiate via a series of precursor stages into terminally differentiated cells 
that acquire specific functions4.  
 
Based on the ability to reconstitute hematopoiesis of irradiated recipients, HSC can 
be divided into long-term (LT-HSCs) and short-term hematopoietic stem cells 
(ST-HSCs). LT-HSCs possess unlimited self-renewal capacity and can therefore 
maintain hematopoiesis for an entire lifespan. ST-HSCs have limited self-renewal 
capacity and reconstitute hematopoiesis only transiently4,5. Both cell types have 
their biological niche with in the bone marrow6. As a progeny of LT-HSCs, ST-HSCs 
differentiate into multipotent progenitors (MPPs) which in turn give rise to the 
common myeloid (CMP) and lymphoid (CLP) progenitors. CMPs that differentiate 
into granulocyte-macrophage progenitors (GMPs) give rise to granulocytes, 
monocytes, dendritic cells, whereas CMPs differentiating into megakaryocyte-
erythrocyte progenitor (MEPs) give rise to erythrocytes and platelets. CLPs 
generate B- and T-cells lymphocytes as well as NK-cells(see Figure 1)3,4,6.  
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For example, erythrocytes deliver oxygen to tissues and organs, platelets assist 
blood clotting during wound healing and tissue repair, and leukocytes are 
components of the innate and adaptive immune systems protecting against various 
biological and chemical intruders. Overall, differentiated blood cells have a limited 
lifespan ranging from several hours (e.g. some granulocytes) up to several decades 
(e.g. memory T cells)6.  
 
A malfunction of the blood system may arise by a cell type not forming e.g. by 
differentiation block or by a cell type not fulfil its function. This can lead to life-
threatening disease or even death. In most of the cases this malfunction is caused 
by a genetic defect. 
 
 
 
 
Figure 1: The hematopoietic system 
During differentiation, HSCs increasingly lose their potential for self-renewal and their proliferation 
rate increases strongly, thus resulting in the enormous expansion capacity of blood cells. 
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1.2 Primary immunodeficiency diseases 
There are over 10.000 known monogenic diseases that are caused by single gene 
mutations. Although most of the monogenic disorders are relatively rare, they 
altogether affect about 0.5 - 1% of newborns and up to 10% of hospitalized 
patients7,8. The best characterized monogenic diseases involve the hematopoietic 
system and include the primary immunodeficiency diseases (PIDs).  
 
PIDs are caused by inherited mutations in genes required for the development 
and/or function of the immune system. Patients with PID lack an intact immune 
system resulting in increased susceptibility to infections, allergens, autoimmune 
reactions and cancer9. PIDs consist of over 200 different diseases which are all rare, 
chronic and usually fatal diseases10. Any component of the immune system can be 
affect a PID.  
In some disorders, only a single part of the system is affected such as chronic 
granulomatous disease (CGD; also see chapter 1.7). In other diseases, there are 
multiple components can be affected such as in severe combined immunodeficiency 
(SCID)11. Defects can be present in adaptive immune system (e.g. SCID and B-cell 
immunodeﬁciencies) or in the innate immune system (e.g. Toll-like Receptor (TLR), 
Natural Killer Cell (NK-cell) and myeloid differentiation primary response gene 88 
(MYD88) deﬁciency)12. Some of the best characterized PIDs are described in some 
more detail below. 
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Table 1: Selected examples of PIDs and their prevalence13,14 
Disease Defect 
Gene 
Mode of 
inheritance 
Prevalence 
Wiskott-Aldrich syndrome (WAS) WASP X-linked 
recessive 
1/250,000 
Selective IgA deficiency (SIgAD1) Unknown Autosomal 
dominant 
1/600 
X-linked agammaglobulinemia (XLA) BTK X-linked 
recessive 
1/200,000 
X-linked severe combined immunodeficiency (X-
SCID) 
IL2RG X-linked 
recessive 
1/50,000 to 
1/100,000 
Adenosine deaminase deficiency SCID ADA Autosomal 
recessive 
1/200,000 to 
1/1,000,000 
JAK3-deficient SCID  JAK3 Autosomal 
recessive 
<1/500,000  
Leukocyte adhesion deficiency type I (LAD1) ITGB2 Autosomal 
recessive 
1/100,000 
X-linked chronic granulomatous disease (X-CGD) CYBB X-linked 
recessive 
1/250,000 
 
Wiskott-Aldrich syndrome (WAS) is a X-chromosomal inherited disease caused by 
mutations in the WAS gene encoding the Wiskott-Aldrich syndrome protein (WASp), 
a cytoskeletal protein expressed by leukocytes and platelets14. WAS patients exhibit 
characteristic Immunologic abnormalities of white blood cells. Besides 
immunodeficiency, patients typically develop other symptoms like skin rashes 
(eczema), thrombocytopenia (low platelet counts), autoimmune reactions and 
malignant lymphoma. As a result, most of the affected patients have a lifespan of 
less than 10 years15–17.  
 
Severe combined immunodeficiency (SCID) summarizes more than 10 different 
genetic disorders characterized by defects in lymphoid development18. Without 
treatment, SCID patients die within the first year of life due to secondary infections. 
The most common form of the disease is X- linked SCID (X-SCID) which is caused 
by mutations in the interleukin-2 receptor gamma chain (IL2RG) gene located on 
the X-chromosome. Since the IL2 gamma chain is shared between receptors for IL-
2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptors, its inactivation results in a complete 
block of T-cells and NK-cell cell differentiation. Therefore, X-SCID patients have no 
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T-cells and NK cells and also lack functional B-cells due to the absence of CD4+ T-
helper cells18,13.  
 
The second most common severe immunodeficiency disease is ADA-SCID, which 
caused by mutations in the adenosine deaminase (ADA) gene. ADA is a key 
enzyme in purine catabolism. Its absence leads to the accumulation of purine 
metabolites in blood plasma, which are toxic to lymphocytes (B, T and NK cells) and 
block their proliferation. Consequently, patients suffer from serious recurrent and 
life-threatening infections13. Symptomatic treatment of SCID aims to minimize 
bacterial, viral and fungal infections by providing sterile environments combined with 
antibiotic, antiviral and antifungal treatment. 
 
Finally, an example for an immunodeficiency of myeloid cells is the chronic 
granulomatous disease (CGD). Granulocyte and macrophages of CGD patients fail 
to kill phagocytosed microorganisms due to an inherited defect of superoxide 
production caused by mutations in genes encoding for the NADPH oxidase 
complex19,20. Since CGD was selected as a disease model gene therapy in this 
theses, it will be described in more detail in the section 1.7. 
 
1.3 Molecular background of PIDs 
A substantial fraction of hereditary monogenic blood disorders are caused by patient 
specific mutations dispersed over the entire locus of the affected gene21. The 
inheritance pattern of most PIDs is either X-linked recessive, autosomal recessive 
or rarely, autosomal dominant13. The mutation type of PID mutations includes point 
mutations, small deletions or insertions, large deletions, duplications, inversions and 
other more complex mutations22,23.  
 
PID mutations can affect any part of the locus: coding regions (exons), the promoter, 
regulatory regions, termination signals, splice donors / acceptors and also introns of 
the genes22. The most frequent PID mutations are in coding exons all resulting in 
protein dysfunction. Commonly there are point mutations which by nucleotide 
replacement create either a premature stop codon (nonsense mutation) or a new 
codon for an unrelated amino acid (missense mutation). Nonsense mutations are 
  Introduction 
12 
 
usually sensed by the splicing machinery and trigger the nonsense mediated decay 
pathway (NMD) resulting in mRNA degradation. As a result, affected cells do not 
express the mutated protein24. However, in some instances the mutated mRNAs 
escape NMD and are translated into truncated proteins. In either case the protein 
function is typically lost23,25.  
Another common type of PID are frameshift mutations. Frameshift mutations can 
involve small deletions or insertions (usually one or two nucleotides) 22 which similar 
to nonsense mutations cause premature stop codons triggering NMD mediated 
mRNA degradation (see above). Figure 2 shows that approximately 77% of the PIDs 
(those shown in the Table 1) are caused by missense, nonsense and frameshift 
mutations and only a minority by more complex mutations.  
 
 
1.4 Hematopoietic stem cell transplantation and gene therapy 
The standard PID treatment is allogeneic hematopoietic stem cell transplantation 
(HSCT). Based on the ability of HSCs to reconstitute the entire hematopoiesis, 
allogeneic HSCT has become the treatment of choice for a variety of congenital and 
acquired diseases, including PIDs and leukemias,26. However, successful allogeneic 
HSCT is largely dependent on the availability of Human Leukocyte Antigen matched 
(HLA-matched) donors. Transplantation of non- non-matched can cause life-
 
Figure 2: Mutation type of the selected examples of PIDs 
Approximately 77% of all mutation are caused by point mutations (missense, nonsense and 
frameshift mutations). Only 23% of the mutations are more complex. 
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threatening graft-versus-host disease (GvHD) during which the engrafted 
lymphocytes elicit an immune response against host tissues perceived as 
foreign27,28. However, 90% of PID patients with appropriate donors undergo 
complete immune reconstitution after HSCT and have a normal life expectancy29. 
Unfortunately, for a significant number of patients HLA-matched donors cannot be 
found. This is particularly problematic in countries where comprehensive blood 
donor catalogs are unavailable30. 
 
The only alternative PID treatment strategy beside symptomatic treatment is gene 
therapy which involves transplantation of autologous HSCs after ex vivo gene 
transfer of a healthy copy of the compromised gene. As shown in Figure 3, gene 
therapy for PIDs includes (i) HSC isolation and purification, (ii) gene transfer by 
either transducing a functional gene copy or by in situ gene repair and (iii) reinfusion 
of the genetically manipulated HSC into the patient.  
 
 
 
Figure 3: In vivo and ex vivo gene therapy concepts 
For the in vivo treatment, the therapeutic gene is introduced directly into the body (e.g. muscle, 
liver) of the patient. For the ex vivo treatment, specific cells are first isolated from the patient body, 
modified in the laboratory with the appropriate vehicle and reinfused into the patient as an 
autologous transplant. BM, bone marrow. (Adopted from Kaufmann et al 20139.) 
  Introduction 
14 
 
The procedure circumvents GvHD and if successful, could be as lifesaving as 
allogeneic HSCT. The problems associated with gene therapy are discussed in 
more details in sections 1.5, 1.6 and 1.8.    
 
 
1.5 Gene transfer vector systems 
One of the greatest challenges of gene therapy is the efficient and safe transfer of 
gene correcting nucleic acids into the diseased cells. During the last 3 decades, 
several cell transduction systems have been developed, ranging from non-viral to 
viral-based vectors (Figure 4). Each system has its unique advantages and 
disadvantages, although for hematopoietic cells significant progress has been made 
with viral vectors to ensure reliable transgene expression with minimal adverse 
effects (see section 1.6)31. The disease itself determines the choice of the gene 
transfer vector.  
 
 
1.5.1 Non-viral vectors 
The prevalent non-viral vectors are expression plasmids consisting of transcription 
units expressing one or more genes of interest after introduction into the nucleus of 
a target cell. Plasmids are transduced into target cells by physical and/or chemical 
means. This process in collectively referred to as transfection. Figure 5 summarizes 
 
Figure 4: Overview of vectors used in gene therapy clinical trials 
(Adopted from http://www.abedia.com/ wiley/images/1602vectors.jpg) 
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the most common transfection methods. The most promising non-viral vectors 
delivered by transfection are liposomes and cationic polymers, which form a  
complex with DNA to form lipoplexes/polyplexes32. These nanomeric complexes are 
stable and enter cells usually by endocytosis31.  
The major advantages of non-viral vectors are its simplicity of preparation, relatively 
low immunogenicity and by chemical low toxicity. Drawbacks are their relatively 
lower efficiency and that they have only terminate expression compared to the viral 
gene delivery31,33,34.  
 
 
An alternative non-viral gene delivery systems for long-term gene expression are 
transposons. Transposon systems are two component systems consisting of a 
transposon which is a genetic element flanked by inverted repeats (this genetic 
element could be any gene of interest) and an enzyme, the transposase, which 
catalyzes cutting and pasting of the transposon in and out of the genome35,36. Unlike 
expression plasmids, transposons integrate stably into the genome and ensure long 
term expression of the inserted gene. Transposons are transduced into target cells 
together with a transposase-expressing plasmid usually by transfection (Figure 6)37. 
Once inside the cell, the transposase triggers transposon integration which, 
depending on the transposon system, occurs more or less randomly throughout the 
genome (Figure 6). Transposons are naturally occurring mobile genetic elements, 
which are common to all organisms. The most popular transposons currently used 
are Sleeping Beauty (SB) and PiggyBac (PB)35–37. However, like the retroviral 
 
Figure 5: Various nonviral gene delivery systems (modified from Manjila et al. 2013) 
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vectors (see below) transposons are insertionally mutagenic and therefore 
associated with adverse effects38–42. 
 
 
1.5.2 Viral vectors 
Viruses are natural nucleic acid transducers that enter susceptible cells by 
interacting with specific cell surface receptors. Once inside the cell, they release 
their genetic material which directs replication via engaging the cellular nucleic acid 
and protein synthesis machineries. In viral vectors, most of the viral genome is 
replaced by one or more genes of interest31,43. Typically, the modified genomes are 
assembled into infectious particles in cell lines expressing the required viral proteins 
from separate expression plasmids44. These cell lines are commonly referred to as 
viral producer or packaging cell lines. 
 
 
Figure 6: Transposon vector system for stable gene delivery (modified from Ivics et al. 
201137) 
Plasmid-based transposon vector system for transgene delivery. A. The vector system consists 
of two components: a plasmid containing a gene of interest (GOI) cloned between the transposon 
terminal inverted repeats (TIR; black arrows) and another plasmid expressing the transposase 
from a suitable promoter (black arrow). B. The transposase protein binds to the TIR of the 
transposon which carries the disered transgene, cleaves in from the donor plasmid and inserts 
the transposon into the genomic DNA. 
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Table 2: Viral vectors and their main properties 
Vectors γ-retrovirus  Lentivirus Adenovirus Adeno-
associated 
virus 
Genome ssRNA ssRNA dsDNA ssDNA 
Packaging 
capacity 
8.8 kb 9.6 kb 8.3 kb 4.8 kb 
Target cells Dividing cells  Dividing and 
Nondividing cells  
Dividing and 
Nondividing cells  
Dividing and 
Nondividing cells  
Integration and 
transgene 
expression 
Yes,  
Stable 
Yes,  
Stable 
No,  
Transient 
No, 
Transient 
(Limited site-
specific 
integration) 
Drawbacks Insertional 
mutagenesis, 
Infects only 
dividing cells 
Insertional 
mutagenesis 
Inflammation 
cytotoxicity, 
Short term 
expression 
Low packaging 
capacity, 
Requires helper 
virus for 
replication 
 
1.5.3 Non-integrating viral vectors 
The most commonly used non-integrating viral vector are based on adenovirus. 
They have been used in 22% of all gene therapy trials including gene therapy of 
cancer and cystic fibrosis45. Adenoviruses are double stranded DNA viruses that do 
not integrate their genome into the host genome. Instead, the adenoviral genome 
remains in the nucleus as an episomal element. Adenoviral vectors are relatively 
easy to produce at high concentrations and efficiently infect a large variety of both 
dividing and non-dividing cells44,46. They express their cargo episomally and 
therefore, only transiently for 7-42 days. As 90% of all people have pre-existing 
antibodies to one or more adenovirus serotypes, the transgene expression can be 
further limited by an immune response eliminating the transduced cells44. Therefore, 
it is advisable to determine anti-Adenoviruse antibody titers prior and during 
adenovirus-based gene therapy. 
 
One alternative to adenoviruses, the adeno-associated viruses (AAV), demonstrate 
low immunogenicity. AAV are single-stranded DNA viruses that require a helper 
virus such as adenovirus or herpes simplex virus. AAV encodes for two proteins, 
rep and cap, which can be provided in-trans for virus production. Thus, to generate 
a recombinant AAV particle, rep and cap can be deleted from the viral genome to 
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leave only the virus inverted terminal repeats (ITRs)45,47. The subtype AAV2 is the 
most commonly used vector. Although AAV belong to the group of non-integrating 
viruses, they still have limited genome insertion sites. An interesting feature of AAV 
is that they tend to stably integrate into the AAVS1 locus on chromosome1948. AAV 
vectors are currently considered the delivery tool of choice for in vivo therapy of 
inherited diseases in post‐mitotic tissues. The major disadvantageous of AAV 
vectors for gene delivery is their limited packaging capacity of up to 4.8 kb31. Another 
limitation is the frequently seen genomic integration of AAV genome into the host 
genome at other sites than AAVS1on chromosome19. Therefore, AAVs and AAV 
vectors are associated with tumorigenesis through insertional mutagenesis mainly 
into the proto-oncogenes48–50  
 
1.5.4 Integrating viral vectors 
The most commonly used integrating viruses are γ-retroviruses and lentiviruses. Y-
retroviruses (e.g. MLV) and lentiviruses (e.g. HIV) belong to the family of 
retroviridae, which are a positive-sense RNA viruses that replicate via a double 
stranded DNA intermediate45. In infected cells the RNA genome is reversely 
transcribed into double-stranded DNA (dsDNA) which integrates randomly 
throughout the genome as a provirus. Reverse transcription and integration are 
catalyzed by the virally mRNA encoded enzymes reverse transcriptase and 
integrase. Proviruses are flanked by repetitive elements known as long terminal 
repeats (LTRs) that ensure viral replication by controlling mRNA transcription and 
processing45,47,51  
 
In retroviral vectors, all genes required for virus replication such as gag (encoding 
viral matrix, capsid, and nucleocapsid proteins), pol (encoding a protease, reverse 
transcriptase, and integrase), and env (encoding a bipartite membrane-anchored 
surface protein) are replaced by a gene of interest45,46,52. To produce replication-
defective infectious particles, the viral vector carrying the genes of interest is co-
expressed with gag, pol and env encoding cassettes in dedicated packaging cell 
lines45,46,52 similar to those described above for adenovirus and AAV production. 
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1.5.5 Vectors of choice for gene replacement therapy in hematopoietic 
stem cells 
Gene-replacement therapy in hematopoietic stem cells requires integrating vectors 
to ensure long term gene expression. Although more recently non-viral transposon 
vectors have been used39–41, the vast majority of clinical trials employed 
γ-retroviral53,54 and lentiviral vectors55–57. All integrating vectors insert semi-
randomly throughout the genome, each having a specific integration pattern dictated 
by distinct features of different genomic regions39,58,59. While γ-retroviral vectors 
(e.g. Moloney Murine Leukemia Virus (MMLV)) preferentially integrate in and around 
transcriptional start sites (TSS), including 5’ regulatory elements such as promoters, 
enhancers, or locus control regions, lentiviral vectors more frequently integrate into 
actively transcribed genes39,59,60. PiggyBac (PB) transposon replicates the 
integration pattern of MMLV whereas Sleeping Beauty (SB) transposon integration 
is arguably more random39 (Figure 7).  
 
 
However, in different γ-retroviral-based clinical trials, site integration induced 
deregulation of genes in the neighborhood and caused perturbation of the cellular 
phenotype. Insertions near oncogenes such as LMO2, MDS1-EVI1, PRDM16 or 
CCND2 led to clonal expansion eventually leading to leukemia. In each case 
leukemia was initiated by an LTR promoter/enhancer-triggered upregulation of 
 
Figure 7: Analysis of integration frequencies around transcriptional start sites (TSS) 
PB and MLV are enriched and HIV and SB are depleted around TSSs (adopted from Gogol-
Döring et al. 201639).  
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oncogene expression (Figure 8b)58,61. In other instances, the therapeutic gene was 
silenced due to LTR promoter methylation15,58,62.  
 
Consequently, next generation gene therapy vectors lacking LTR 
promoter/enhancer elements were developed in which the therapeutic gene is 
expressed from an internal (maybe tissue-specific) promoter (Figure 8c). Clinical 
trials with these vectors commonly referred to as self-inactivating (SIN) vectors 
showed a substantially improved safety profile and less susceptibility to gene 
inactivation63,64.  
 
 
 
 
Figure 8: Mechanisms of the insertional mutagenesis mediated by the retroviral vectors 
a) Vector integrations site is displayed in the first intron of a proto-oncogene. b) Y-retroviral vector 
integration in the first intron of a proto-oncogene could lead to upregulated transcription of the 
proto-oncogene from its cellular promoter by enhancer-mediated effects. Alternatively, 
expression driven by the 5′ LTR or 3′ LTR could give rise to a chimeric transcript an N-terminally 
truncated form of the oncogene. c) Self-inactivating (SIN) LTRs show improved are to be more 
safety and the expression of the therapeutic gene from an internal promoter is more robust (form 
Naldini L, 201158). 
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Currently, most clinical gene therapy trials employ third generation lentiviral vectors 
which are self-inactivating and usually rely on lineage-specific promoters9,65. 
Although significantly less genotoxic than the earlier vector generations, the self-
inactivating (SIN) lentiviral vectors are not entirely safe66. They can still activate 
oncogenes from the internal promoter/enhancer elements as has been shown for 
Braf and Mak3k8 and inactivate tumor suppressor genes as has been shown for 
Pten and Rasa166. Thus, ideally gene replacement strategies would be substituted 
by designer endonuclease strategies capable of in situ gene correction (see below). 
 
1.6 Clinical gene therapy trials for the treatment of PIDs 
Over the last 3 decades, the curative potential of gene therapy has been 
demonstrated in many clinical phase I / II PID gene therapy trials67,68. An overview 
of the most important past and ongoing PID gene therapy trials is given in Table 3. 
 
There are many requirements for a successful gene therapy: a clear understanding 
of the molecular biology and genetics of the disease, the availability of tissue or cell 
targeted for the gene delivery, an effective therapeutic vehicle and an animal model 
that closely simulates the disease for preclinical studies. 
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Table 3: Clinical trials of HSC-based gene-therapy in PIDs 
Disease Therapeutic 
Gene 
Total 
Patients 
Vector/ 
Transcriptional 
Control 
Element 
Method Patient status and 
biological and 
clinical outcomes 
Reference/ 
Clinical-trial 
identifier 
WAS WASP  3 LV / human 
endogenous 
WAS gene 
promoter 
ex vivo 
gene 
transfer 
into 
CD34+ 
All patients AAW; 
stable engraftment with 
transduced cells; 
persistent clinical 
benefit and safety 
16 
NCT01515462 
WAS WASP  7 LV / human 
endogenous 
WAS gene 
promoter 
ex vivo 
gene 
transfer 
into 
CD34+ 
6 patients AAW, 1 
patient died of a pre-
existing infection; 
stable engraftment with 
transduced cells; 
persistent clinical 
benefit and safety 
69 
NCT01347242 
NCT01347346 
NCT02333760 
X1-SCID γc  9 SIN-γ-RV / 
human EF1α 
short 
ex vivo 
gene 
transfer 
into 
CD34+ 
8 patients AAW, 1 
patient died of an 
adenoviral infection; 
stable engraftment with 
transduced cells; 
persistent clinical 
benefit and safety in 7 
patients 
70 
NCT01410019 
NCT01175239 
NCT01129544 
X1-SCID γc  10 γ-RV / MFG-
LTR 
ex vivo 
gene 
transfer 
into 
CD34+ 
4 of 10 developed T 
cell leukemia; 
Insertions near the 
LMO2 proto-oncogene; 
1 patient died 
71,72 
 
ADA-SCID ADA  10 γ-RV / MLV-
LTR 
ex vivo 
gene 
transfer 
into 
CD34+ 
All patients AAW; 
stable engraftment with 
transduced cells; 
persistent clinical 
benefit and safety in 9 
patients 
73 
NCT00598481 
NCT00599781 
AR-CGD NCF1  5 γ-RV / MLV-
LTR 
ex vivo 
gene 
transfer 
into 
CD34+ 
No clinical beneﬁt 74 
X-CGD CYBB  2 γ-RV /SFFV-
LTR 
ex vivo 
gene 
transfer 
into 
CD34+ 
Both patients 
developed functional 
neutrophils and 
developed MDS with 
monosomy 7 from 
insertional activation of 
MDS1-EVI1, PRDM16, 
SETBP1; 1 patient 
died 
62,75 
NCT00564759 
      AAW: alive and well 
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Taken together, these studies showed that clinical outcome is highly dependent on 
the transduction efficiency of hematopoietic cells capable of engrafting and 
functionally reconstituting the patient’s hematopoiesis. However, clinical success 
was also dependent on the particular disease. While positive selection imposed on 
genetically reconstituted cells in patients with immunodeficiency diseases (e.g. X-
SCID, ADA-SCID) increased the success rate, lack of such selection in patients with 
CGD was clearly detrimental because the non-modified, residual cells outcompeted 
the transplanted cells during hematopoietic regeneration9,76,77. 
 
1.7 Chronic granulomatous disease 
Chronic granulomatous disease (CGD) is a rare inherited immunodeficiency 
affecting 1 in 250,000 individuals78. CGD is characterized by the inability of 
phagocytes to eliminate ingested pathogens and is caused by mutations in any of 
the five genes of nicotinamide dinucleotide phosphate (NADPH) oxidase complex. 
In neutrophils, eosinophils, monocytes, and macrophages NADPH oxidase reduces 
molecular oxygen to reactive oxygen species (ROS) such as superoxide anion (O2-), 
hydrogen peroxide (H2O2), hypochlorite ion (HOCl) and hydroxyl radical (OH-), 
which kill the ingested microorganisms (Figure 9). Deficiencies of NADPH result in 
severe, recurrent and life-threatening bacterial and fungal infections such that 
affected patients require lifelong prophylactic treatment with antibiotics, antifungals 
and interferon gamma (IFN-γ)78–81. To date, the only curative treatment for CGD is 
allogeneic bone marrow transplantation79,80,82 which is limited to patients having a 
suitable HLA-matched donor78,81,82. 
 
CGD is a genetically heterogeneous disease. Approximately, 60-70% of all CGD 
mutations affect the X-chromosomal CYBB gene encoding the protein gp91phox (X-
CGD). The other 30% have mutations in either the CYBA, NCF1, NCF2 or NCF4 
genes encoding for p22phox, p47phox, p67phox, and p40phox, respectively. Unlike the X-
linked CYBB mutations, these mutations are inherited in an autosomal recessive 
manner (AR-CGD)78,80,82,83.  
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1.8 Gene therapy for X-CGD 
For X-CGD patients lacking a suitable donor, ex-vivo gene therapy combined with 
autologous bone marrow transplantation is the most promising therapeutic 
alternative. As has been shown previously in animal models and clinical trials, 
reconstitution of CYBB in only 5-10% of neutrophils is sufficient to cure the 
disease19,20,84. 
 
Several phase I/II gene therapy trials of X-CGD demonstrated the therapeutic 
potential transplantation of autologous HSCs retrovirally transduced ex vivo with 
retroviral vectors carrying healthy copies of CYBB for the treatment of X-CGD. The 
first X-CGD trial included five adult patients who received ex-vivo manipulated 
autologous HSC without myelosuppressive preconditioning resulting in less than 1% 
CYBB reconstitution85. The second trial enrolled two adults (P1=26 years; P2=25 
years) and was performed at Goethe-University Frankfurt. Unlike in the preceding 
trial, the patients received myelosuppressive preconditioning to enable the 
engraftment of genetically manipulated HSCs75. Both trials employed γ-retroviral 
vectors expressing the CYBB cDNA from the LTR promoter. The Frankfurt patients 
 
Figure 9: NADPH oxidase complexes in phagocytic cells 
The NADPH oxidase comprises a membrane-bound gp91phox/p22phox heterodimer and other 
subunits (p67phox, p47phox, p40phox and Rac) which associates with this complex in the 
activated enzyme. The active NADPH produces reactive oxygen species (ROS) which are 
essential in defense against invading microbial pathogens. 
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fared well for up to 5 months post-transplantation. In both patient CYBB function 
could be reconstituted in over 15% of granulocytes, leading to the eradication of 
preexisting life-threatening infections75. However, after 5 months some CYBB-
expressing cells underwent clonal expansion due to insertional activation of several 
oncogenes (i.e. PRDM16, MDS1/EVI1 and SETBP1). Although this temporarily 
increased the number of modified granulocytes from 15% to about 60%, CYBB 
expression was eventually silenced by LTR promoter methylation62,75,86. Intriguingly, 
the LTR enhancer was not affected and continued to transactivate the nearby proto-
oncogenes. In the end, EVI1 overexpression in both patients led to the genomic 
instability and preleukemic myelodysplasia with monosomy 762,86. 
 
Similar genotoxicity was observed in an 8.5 year old boy treated in Zürich according 
to the Frankfurt protocol (Table 4). In all 3 further studies involving gamma-retroviral 
vectors and patient preconditioning the genetically manipulated cells failed to 
engraft (Table 4)85. 
 
Table 4: Summary of gene therapy trials for X-CGD including myelosuppressive strategies 
(Modified form Grez et al. 201185.) 
Center  Total 
Patients 
Total 
conditioning 
Vector/ 
Transcriptional 
Control 
Element 
Significant  
engraftment   
>3 months 
Genotoxicity Reference 
Frankfurt  2 Liposomal 
busulfan, 8.0 
mg/kg  
SF71gp91phox  
(SFFV-LTR) 
15% gene 
marking in 
CD15+ cells 
Both patients 
developed clonal 
myeloproliferation 
and MDS with 
monosomy 7 
62,75 
Zürich 1 Liposomal 
busulfan, 8.8 
mg/kg 
SF71gp91phox  
(SFFV-LTR) 
20% gene 
marking in 
CD15+ cells 
Development of 
clonal 
myeloproliferation 
87 
London 1 Melphalan,  
140 mg/m2 
MFGS-gp91phox 
(MLV-LTR) 
   
    No No   
 3  SF71gp91phox  
(SFFV-LTR) 
   
NIH 3 Busulfex, 10 
mg/kg 
MFGS-gp91phox  
(MLV-LTR) 
No No 84 
Seoul 2 Busulfex, 6.4 
mg/kg + 
fludarabine, 
120 mg/m2 
MFGS-gp91phox 
(MLV-LTR) 
No No 88 
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Overall, the clinical X-CGD gene therapy revealed that CYBB function can be 
temporarily restored by ex vivo gene replacement although the toxicity of the 
employed strategy is prohibitively high, suggesting that significantly safer protocols 
are required, which guarantee a long-term and safe gene therapy.  
 
1.9 Site-specific endonucleases 
Over the last few decades, the tools available for genome manipulation have 
advanced significantly. Genome editing/engineering is widely used in the basic 
research to specifically knock-in or knock-out genes in given target cells (e.g. 
viruses, single cell organisms, plants, even vertebrates). Furthermore it is used for 
development of novel therapies. A wide array of powerful gene editing systems are 
now available, which are called engineered or designer endonucleases89,90. 
Designer endonucleases are engineered enzymes that can introduce DNA double 
strand breaks (DSBs) with high specificity into the desired target sequences. To be 
useful for genome engineering, the endonucleases must have two particular 
functions. First, there must be a specific recognition domain (protein or RNA) which 
recognizes long target sequences (ideally, long enough for unique occurrence in the 
eukaryotic genome). Second, they must cleave in the targeted sequence. To date, 
four types of endonucleases exist; (1) meganucleases, (2) zinc finger nucleases 
(ZFNs), (3) transcription activator–like effector nucleases (TALENs) and (4) 
CRISPR-associated nuclease Cas9.  
 
1.9.1 Meganucleases 
Meganucleases (also called homing endonucleases) are natural 
endodeoxyribonucleases characterized by a large target recognition sites (14-40 
bp)91,92 which generally occur only once in any given genome. They are found in 
bacteria, archaea, phages, protists, fungi, and plants93,94. Although the isolation of 
natural meganucleases with new target specificities is tedious and slow, target 
specificity can be modified in existing meganucleases by protein engineering92,93. 
However, such modifications are challenging92,93. 
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1.9.2 Zinc-finger nucleases 
Zinc-finger nucleases (ZFNs) are chimeric endonucleases, consisting of individual 
zinc-finger protein (ZFP) DNA binding motifs fused to the cleavage domain of the 
FokI restriction endonuclease95. ZFNs typically contain between 3 – 6 ZFP motifs. 
Each motif recognizes 3 – 4 bp, which results in a recognitionsite of typically 
9 – 18 bp90,96. As the FokI cleavage domains acts only in form of a dimer in order to 
cleave DNA and therefore a pair of ZFNs targeting the sense and antisense strand 
are required90,97. The main drawback of the ZFNs is the limited number of available 
ZFP motifs and that the individual ZFP domains do not independently bind to their 
specific DNA element but rather influence the binding of the neighboring domain, 
which results in many ZFNs leading to off-target effects. This cooperative binding 
makes the ZFN design difficult and time consuming as it requires sophisticated 
protein engineering and specialized methodology, thus preventing their widespread 
use90,98.  
 
1.9.3 Transcription activator-like effectors nucleases 
Transcription activator-like effectors nucleases (TALENs) are, similar to ZFNs, 
chimeric endonucleases in which a transcription activator-like effector (TALE) DNA 
binding domain is fused to the DNA cleavage domain of FokI99,100. The DNA binding 
domains consist of highly conserved 33-35 amino acid sequence in which only the 
amino acid located at the position 12 and 13 vary. These two positions, referred to 
as the Repeat Variable Diresidue (RVD), are highly variable and responsible for 
specific base pair recognition 90,99. Naturally, TAL effector proteins are secreted by 
Xanthomonas bacteria during plant infection resulting in the modulation of gene 
expression100. In contrast to ZFN the individual domains do not influence binding of 
the neighboring domain, making TALENs design and assembly is relatively simple 
as it does not require extensive screening for target specificity99–102. Central 
problems with TALENs are, that they are sensitive to cytosine methylation, 
especially at CpG region and many TALEN pairs provide little or no mutagenesis 
activity. 
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1.9.4 Clustered regularly interspaced short palindromic repeats/Cas9 
Clustered regularly interspaced short palindromic repeats (CRISPR) are defining 
components of the genomes of most bacteria and archaea and are part of their 
adaptive immune system defending then against phage and plasmid DNA 
infection103. The first report on the CRISPR array were from 1987 by Ishino and 
colleagues, who found in E.coli 29 nt repeats that were interspersed by 32 nt long 
non-repetitive sequences (spacers)104. Three different types of CRISPR/Cas9 
systems have been characterized thus far. The most widely used CRISPR/Cas9 
system of Streptococcus pyogenes (spCas9/sgRNA) consists of three components: 
the CRISPR-associated DNA cleaving endonuclease Cas9 protein (~160 kDa, ~4.2 
kb), a target DNA sequence recognizing RNA which is transcribed from short DNA 
sequences known as protospacers that are separated by short palindromic 
sequences clustered in the bacterial genome in the CRISPR array, (crRNA), and a 
trans-activating crRNA (tracrRNA) required for crRNA transcription90,105. For 
genome editing, the crRNA and tracrRNA were fused into a fully functional single 
guide RNA (sgRNA) of 110 nt105. Additionally, functional spCas9 requires a so called 
protospacer adjacent motif (PAM) sequence (i.e. 5‘NGG) located downstream of the 
sgRNA target sequence which determining the exact position of DNA cleavage 
occurring always 3 nt upstream of the PAM106. Cas9 consists of the HNH- and the 
RuvC-like nuclease domains, which cleave the coding and the non-coding DNA 
strands, respectively. Unlike the other designer endonucleases, CRISPR/Cas9 is 
addressed to the target site solely by a RNA molecule, without any protein 
engineering107–109. Since the CRISPR/Cas9 system relies on RNA/DNA base-
pairing it circumvents problems encountered with the other, protein based editing 
systems such as inactivating methylations and does not require protein engineering. 
CRISPR/Cas9 RNA-guided nucleases (RGNs) are easy to make and can be applied 
to a large variety of genome editing tasks including targeted gene activation, multiple 
gene targeting (multiplexing) and epigenetic manipulation110–112. 
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1.10 Molecular outcomes of genome editing 
DSB generated by site-specific designer endonuclease activate the cellular repair 
machinery which restores the lesion either by homology directed repair (HDR) or by 
non-homologous end joining (NHEJ). HDR is an error-free process because it 
requires a donor DNA sequence as a repair template90,111. Thus, HDR can be 
exploited to create specific sequence changes, including the targeted addition of 
whole genes (knock-ins)90,113,114. In contrast, NHEJ restores DSBs in absence of a 
template by religating the DNA ends – a process associated with random nucleotide 
insertions or deletions (indels)109,114. Because indels frequently cause mutations, 
designer endonuclease systems and in particular the CRISPR/Cas9 system are 
being employed extensively for functional genetic screens115–117 and for the 
accelerated production of knock-out animals118–121. However, designer 
endonucleases also have the potential to correct genetic mutations directly in 
affected tissues and cells to treat diseases that are not curable by traditional 
therapies (Table 5)97,111,122–124. 
 
Table 5: Examples of applications of genome editing to therapeutic model disease. 
(Adopted from Cox et al. 2015111)  
Disease type Nuclease 
platform 
Therapeutic strategy Reference 
Hemophilia B  ZFN HDR-mediated insertion of correct gene 
sequence 
125 
HIV ZFN and CRISPR NHEJ-mediated inactivation of CCR5 126–129 
Duchenne 
muscular 
dystrophy (DMD) 
TALEN and 
CRISPR 
NHEJ-mediated removal of stop codon 
 
HDR-mediated gene correction 
130,131 
Hepatitis B virus 
(HBV) 
TALEN and 
CRISPR 
NHEJ-mediated depletion of viral DNA 
HDR-mediated 
132,133 
SCID ZFN HDR-mediated insertion of correct gene 
sequence 
134 
Cataracts CRISPR HDR-mediated correction of mutation in 
mouse zygote 
124 
Cystic fibrosis 
Hereditary 
CRISPR HDR-mediated correction of CFTR in 
intestinal stem cells 
135 
Hereditary 
tyrosinemia 
CRISPR HDR-mediated correction of mutation in 
liver 
136 
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1.11 Aim of this work 
A large part of hereditary monogenic disorders affecting the hematopoietic system, are 
caused by patient-specific mutations spread over the entire locus of the affected gene. 
These patients often lack an intact immune system resulting in increased susceptibility 
to infections, allergens, autoimmune reactions and cancer. Designer endonucleases, 
especially CRISPR/Cas9, hold the potential to significantly improve the results of future 
clinical personalized gene therapy approaches for these patients. Hitherto, the 
correction of monogenic disorders using designer endonucleases are primarily based 
on homology directed repair (HDR), which is dependent on an exogenous DNA 
template. The efficiency of the gene correction by means of HDR is generally very low, 
reduced even further by the cell cycle dependence of HDR, Additionally, in 
hematopoietic stem- and progenitor cells (HSPC) the dominant DSB-repair pathway is 
the NHEJ pathway.  
 
The aim of this thesis was to develop a template-free NHEJ-mediated DNA repair 
strategy for personalized gene therapy of primary immunodeficiency diseases (PIDs) 
using site-specific designer endonucleases. In theory, approximately one third of the 
indels associated with NHEJ should restore the open reading frame (ORF) disrupted 
by a particular disorder point mutation. Depending on the location and type of the point 
mutation, some of the reconstituted ORFs should either completely or partially recover 
protein function. The following objectives were tackled: 
 
 Comparing the efficiency of the DSB repair mechanism of HDR vs. NHEJ using 
site-specific designer endonucleases 
 Restore a point mutated Hprt gene by NHEJ to reconstruction the non-mutated 
gene 
 Generate a restore a point mutated EGFP reporter  
 Generate cell lines expressing a single copy CYBB reporter genes harboring 
patient specific point mutations 
 Test the efficiency of CRISPR/Cas9-mediated gene correction delivered by 
integrase-defective lentiviral (IDLV) into the mutant CYBB target cells   
 Estimate the target mutation efficiency at the endogenous CYBB locus in human 
hematopoietic cells 
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2. Materials and Methods  
2.1 Material 
2.1.1 Software and online tools 
Name Manufacturer 
ApE-A plasmid Editor by Mikel Wayne Davis (University of Utah) 
Benchling (CRISPR predictor) https://benchling.com/ 
CCTop - CRISPR/Cas9 (CRISPR predictor) http://crispr.cos.uni-heidelberg.de/ 
Clustal Omega (Multiple Sequence Alignment) http://www.ebi.ac.uk/Tools/msa/clustalo/ 
CYBBbase variation browser http://structure.bmc.lu.se/idbase/ 
CYBBbase/browser.php?content=browser 
Diva7 FACS‐software Becton Dickinson, Franklin Lakes, USA 
Ensembl http://www.ensembl.org/index.html 
Flowing software 2.5.1 http://flowingsoftware.btk.fi/ 
GraphPad Prism 5 GraphPad software, La Jolla, USA 
Lasergene 7 DNASTAR, Madison, USA 
Mendeley Desktop Elsevier, Amsterdam, Netherlands 
Microsoft Office 2013 Microsoft, Redmond, USA 
Oligo Tm Analyzer http://tmcalculator.neb.com/#!/ 
Quantity One 1-D analysis software  Bio-Rad, Hercules, USA 
SMART modular architecture research tool http://smart.embl-heidelberg.de/ 
 
2.1.2 Hardware and consumables 
Device Manufacturer 
Analytical balance Sartorius, Göttingen, Deutschland 
Agarose gel electrophoresis power supply - EPS 
500/400 
Pharmacia LKB, Uppsala, Sweden 
Agarose gel running chamber - 40-0911 Peqlab Biotechnologie, Erlangen, Germany 
Bacteria shaker Roth KS 15A Roth, Karlsruhe, Germany 
Centrifuge - Rotina 35 Hettich, Tuttlingen, Germany 
Centrifuge – Rotanta 460 Hettich, Tuttlingen, Germany 
Centrifuge - Microcentrifuges 5424 Eppendorf, Hamburg, Germany 
BD FACSAriaTMIII Becton Dickinson, Franklin Lakes, USA 
BD LSRFortessaTM Becton Dickinson, Franklin Lakes, USA 
Gel documentation system - E.A.S.Y.RH-3 Herolab, Wiesloch, Germany 
incubator Heraeus B6030 (Bacteria) Thermo Fisher Scientific, Massachusetts, USA 
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Incubator Heracell 150i Thermo Fisher Scientific, Massachusetts, USA 
Microscope Zeiss ID03 Zeiss, Jena, Germany 
NanoDrop 2000c Thermo Fisher Scientific, Massachusetts, USA 
NucleofectorTM 2b Lonza, Basel, Switzerland 
Odyssey FC LI-COR Bioscience, Bad Homburg, Germany 
PAGE Power supply - Power Pac 1000 Bio-Rad, Hercules, USA 
PAGE system - XCELL SureLockTM Invitrogen, Carlsbad, USA 
Pipette  Gilson, Middleton, USA 
PCR device - Mastercycler® pro Eppendorf, Hamburg, Germany 
PCR device – T100TM Thermal Cycler Bio-Rad, Hercules, USA 
pH-meter - Hanna pH 210 Hanna instruments, Woonsocket, USA 
Photometer Eppendorf, Hamburg, Germany 
Quadro‐MACS cell separator Miltenyi Biotech, Bergisch Gladbach, Germany 
Sonifier – VW 2070 Bandelin electronic, Berlin, Germany 
Laminar flow; Sterile bank Class II Nuaire Zapf Instruments, Sarsted, Germany 
Table centrifuge - Himac CT15RE Hitachi, Tokio, Japan 
Thermocycler - MastercyclerRPro Eppendorf, Hamburg, Germany 
Wet Transfer blot module - XCELL II TM Blot 
Module 
Invitrogen, Carlsbad, USA 
Ultracentrifuge - Optima™ XPN 80K Beckman Coulter, Brea, USA 
Vortexer VF-2 Janke&Kunkel IKA, Staufen, Germany 
Water bath GFL1083 GFL, Burgwedel, Germany 
 
2.1.3 Plastic ware and consumables 
Item Manufacturer 
Cell culture flasks, plates and dishes Greiner bio-one, Kremsmünster, Austria 
Filter Tips  StarLab, Hamburg, Germany 
Flow cytomtry tubes Sarstedt, Nümbrecht, Germany 
Tips StarLab, Hamburg, Germany 
Mikrofilter (0,22µm, 045µm) Merck Millipore, Darmstadt, Germany 
1.5 – 2 ml reaction tubes Sarstedt, Nümbrecht, Germany 
15 – 50 ml reaction tubes Sarstedt, Nümbrecht, Germany 
PCR tubes Greiner bio-one, Kremsmünster, Austria 
Ultracentrifuge tubes  Beckman Coulter, Brea, USA 
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2.1.4 Chemicals and reagents 
Chemical Manufacturer 
1 kB plus DNA ladder NEB, Frankfurt, Germany 
2-Propanol Sigma-Aldrich, Taufkirchen, Germany 
10x Restriction buffer 1,2,3,4 New England Biolabs, Frankfurt, Germany 
Acrylamide 40% Amresco, Solon, USA 
Agarose Roth, Karlsruhe, Germany 
Ampicillin sodium salt Roth, Karlsruhe, Germany 
APS 10% Roth, Karlsruhe, Germany 
Antarctic Phosphatase Buffer 10x NEB, Frankfurt, Germany 
Bovine Serum Albumine (BSA) Applichem, Darmstadt, Germany 
Chloroform Fluka, Deisenhofen, Germany 
Chloroquine Sigma-Aldrich, Taufkirchen, Germany 
DMEM Gibco, Karlsruhe, Germany 
dNTP mix (10 µM each) NEB, Frankfurt, Germany 
Dihydrorhodamine123 Sigma-Aldrich, Taufkirchen, Germany 
Dimethylsolfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreitol (DTT) AppliChem, Darmstadt, Germany 
ddH2O Sigma-Aldrich, Taufkirchen, Germany 
Ethylenediaminetetraacetic acid (EDTA) Roth, Karlsruhe, Germany 
Ethanol Sigma-Aldrich, Taufkirchen, Germany 
Ethidiumbromide Roth, Karlsruhe, Germany 
Fetal calf serum (FCS) Sigma-Aldrich, Taufkirchen, Germany 
Formaldehyde Merck, Darmstadt, Germany 
Glycerol Roth, Karlsruhe, Germany 
Glycine Merck, Darmstadt, Germany 
Hydrochloric acid (HCl) Roth, Karlsruhe, Germany 
HDGreen Plus Intas, Göttingen, Germany 
HEPES Roth, Karlsruhe, Germany 
Isopropanol Fluka, Deisenhofen, Germany 
LB-Agar Roth, Karlsruhe, Germany 
LB-Medium Roth, Karlsruhe, Germany 
L‐glutamine PAA Laboratories, Pasching, Austria 
Methanol Merck, Darmstadt, Germany 
Methylene blue Sigma-Aldrich, Taufkirchen, Germany 
Sodium chloride (NaCl) Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) Roth, Karlsruhe, Germany 
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NBT Sigma-Aldrich, Taufkirchen, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen, Germany 
PBS (w/o Ca2+ Mg2+) PAA Laboratories, Pasching, Austria 
Penicillin/Streptomycin (100x) PAA Laboratories, Pasching, Austria 
PMA Sigma-Aldrich, Taufkirchen, Germany 
Polyethylenimin (PEI) Sigma-Aldrich, Taufkirchen, Germany 
Polybrene Sigma-Aldrich, Taufkirchen, Germany 
Ponceau S AppliChem, Darmstadt, Germany 
Precision Protein Standard Biorad, Richmond, USA 
Q5 ® Polymerase Buffer 5X NEB, Frankfurt, Germany 
Red Taq Buffer 10x Sigma-Aldrich, Taufkirchen, Germany 
Restriction Buffers 10x NEB, Frankfurt, Germany 
RPMI Gibco, Karlsruhe, Germany 
Sucrose Roth, Karlsruhe, Germany 
SuperSignal® West Femto Luminol/ Enhancer 
Solution 
Thermo Scientific, Rockford, USA 
SuperSignal® West Fermto Stable Peroxide 
Solution 
Thermo Scientific, Rockford, USA 
SuperSignal® West Pico Luminol/ Enhancer 
Solution 
Thermo Scientific, Rockford, USA 
SuperSignal® West Pico Stable Peroxide 
Solution 
Thermo Scientific, Rockford, USA 
T4 DNA ligase Buffer NEB, Frankfurt, Germany 
TEMED Roth, Karlsruhe, Germany 
Triton X-100 Sigma-Aldrich, Taufkirchen, Germany 
Trypan blue Sigma-Aldrich, Taufkirchen, Germany 
Tween-20 Roth, Karlsruhe, Germany 
Tris Roth, Karlsruhe, Germany 
X‐Gal Sigma-Aldrich, Taufkirchen, Germany 
beta-Mercaptoethanol Fluka, Deisenhofen, Germany 
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2.1.5 Buffers and solutions 
Buffer Composition 
Blocking buffer (WB) 5% non-fat milk powder 
in 1X TBS-T 
Bis-Tris buffer 1.25 M Bis-Tris 
pH 6.5 
in H2O 
DNA-loading Buffer (10x) 100 mg Bromophenol blue 
100 mg Xylen cyanol  
33 ml 150 mM Tris pH 7.6 
60 ml Glycerol 
7 ml H2O 
FACS fixation solution 2% formaldehyde  
in PBS 
LB Agar 35 g agar powder mix 
in 1 l H2O 
LB medium 20 g LB broth mix 
in 1 l H2O 
MACS buffer 0.5% BSA 
2 mM EDTA 
in PBS pH 7.2 
SDS cell-lysis buffer for gDNA 50 mM Tris-HCl pH 8 
100 mM NaCl  
1 mM EDTA pH 8 
0,5% SDS 
SDS cell-lysis buffer for protein 100 mM Tris-HCl pH 8 
150 mM NaCl  
10 mM EDTA pH 8 
10% SDS 
SDS sample buffer (4X) 250 mM Tris-HCl pH 6.8 
8% SDS 
40% glycerol 
0.2% bromphenolblue 
Sorting buffer 2% FCS 
1% Pen/Strep 
1 mM EDTA 
in PBS 
TAE buffer (50X) 242 g Tris  
57.1 ml Acetic acid 
100 ml EDTA (0.5M) pH 8.0 
TBS-T 100 mM Tris-HCl pH 7.4 
150 mM NaCl 
0.05% Tween-20 
Western Blot lysis buffer  50 mM Tris pH 7.4,  
0.15 M NaCl,  
2 mM EDTA,  
1% NP-40 
in H2O 
20% sucrose 100 g sucrose  
400 ml PBS 
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2.1.6 Enzymes  
 
2.1.7 Commercially available kits 
 
2.1.8 FACS antibodies 
Antigen Fluorophore Target spec. Manufacturer 
CD11b APC Human Becton Dickinson, 
Franklin Lakes, USA 
CD34 PE / APC-Cy7  Human Miltenyi Biotech, 
Bergisch Gladbach, 
Germany 
CYBB(7D5) FITC Human MBL, Nagano, Japan 
 
 
Enzyme Manufacturer 
Antarctic Phosphatase NEB, Frankfurt, Germany 
RedTaq Polymerase Sigma-Aldrich, Taufkirchen, Germany 
Proteinase K Sigma-Aldrich, Taufkirchen, Germany 
Restriction Endonucleases NEB, Frankfurt, Germany 
Q5 ® High-Fidelity DNA Polymerase NEB, Frankfurt, Germany 
T4 DNA ligase NEB, Frankfurt, Germany 
Trypsin‐EDTA (10x) Sigma-Aldrich, Taufkirchen, Germany 
Name Application Manufacturer 
Amaxa® Cell Line Nucleofector 
Kit® V 
DNA Nucleofection in cells Lonza, Basel, Switzerland 
DNA Clean & ConcentratorTM -
5 
DNA cleaning  Zymo Research, Irvine, USA 
Human CD34 isolation kit Cell isolation Miltenyi Biotech, Bergisch 
Gladbach, Germany 
Nucleobond PC 500 Plasmid preparation (Maxi) Macherey‐Nagel, Düren, 
Germany 
TOPO‐TA cloning kit PCR‐fragment cloning Invitrogen, Carlsbad, USA 
ZymocleanTM Gel DNA 
Recovery Kit 
Gel extraction Zymo Research, Irvine, USA 
Surveyor® Mutation Detection 
Kit 
Detect mutations in DNA IDT, Coralville, USA  
p24 ELISA kit (INNOTEST) Viral titer determination Fujirebio, Hannover, Germany 
  Materials and Methods 
37 
 
2.1.9 Western blot antibodies 
Antigen Working dilution Species  Target spec. Manufacturer 
EGFP 1:1000 mouse  Roche, Basel, 
Switzerland 
GAPDH 1:1000 rabbit human Cell Signaling, 
Frankfurt am Main, 
Germany 
CYBB (moAB48) 1:500 mouse human LifeSpan 
BioSciences, 
Seattle, WA, USA 
Note: All the antibodies were diluted in 5% low-fat milk. 
 
2.1.10 Cytokines 
Cytokine Manufacturer 
Human Flt‐3 Peprotech, New Jersey, USA 
Human G‐CSF Peprotech, New Jersey, USA 
Human IL‐3 Peprotech, New Jersey, USA 
Human SCF Peprotech, New Jersey, USA 
Human TPO  Peprotech, New Jersey, USA 
 
2.1.11 Plasmids 
Name Function Source 
psPAX2 HIV‐1 packaging plasmid encoding 
for gag, pol, rev und tat under 
control of the CMV promoter 
Addgene (ID: 12260) 
psPAX2-D64V HIV‐1 packaging plasmid encoding 
for gag, pol, rev und tat under 
control of the CMV promoter 
Addgene (ID:63586) 
pMD2.G Packaging plasmid expressing the 
VSV‐envelope under control of the 
CMV promoter 
Addgene (ID:12259) 
pCAG-T7-TALEN1 HPRT  Genome editing Obtained from R. Kuhn 
pCAG-T7-TALEN2 HPRT  Genome editing Obtained from R. Kuhn 
pmaxGFP Nucleofection control vector 
encoding GFP under control of the 
CMV promoter 
Lonza, Cologne, Germany 
pHPRT-P2A-EGFP-pA Donor vector for targeting HPRT 
locus 
This thesis 
pHR‘SIN‐SEW HIV‐1 transfer‐vector encoding 
EGFP under control of the SFFV 
promoter, contains WPRE, SIN‐
configuration 
Obtained from M. Grez 
Demaison et al. 2002137 
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pHR‘SIN‐SBW HIV‐1 transfer‐vector encoding 
TagBFP (developed from 
TagRFP138) under control of the 
SFFV promoter, contains WPRE, 
SIN‐configuration 
Obtained from M. Grez 
 
pHR‘SIN-SBGW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
EGFP 
This thesis 
pHR‘SIN-SBmGW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
mutEGFP 
This thesis 
pHR‘SIN-SBCW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
CYBB 
This thesis 
pHR‘SIN-SB45CW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
45CYBB 
This thesis 
pHR‘SIN-SB54CW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
54CYBB 
This thesis 
pHR‘SIN-SB134CW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
134CYBB 
This thesis 
pHR‘SIN-SB173CW Same configuration as pHR‘SIN‐
SBW, encoding TagBFP-IRES-
173CYBB 
This thesis 
phCas9 Expresses human codon optimized 
Cas9 nuclease for genome 
engineering under control of the 
CMV promoter 
Addgene (ID:41815) 
pgRNA Cloning Vector An empty gRNA expression vector, 
used to create a gRNA to a specific 
sequence under control of the hU6 
promoter 
Addgene (ID:41824) 
pLentiCRISPRv2 contains two expression cassettes, 
hSpCas9 + Puro under control of the 
EF1α-short promoter and the 
chimeric guide RNA under control of 
the hU6 promoter 
Addgenee (ID:52961) 
pLentiCRISPRv2ΔPuro Same configuration as 
pLentiCRISPRv2 delta-Puro 
This thesis 
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2.1.12 Cell lines and culture media 
Name Genotype Media Source 
HEK293T Human embryonic kidney cell line 
genetically engineered to express the 
large T antigen 
DMEM  
10% FCS  
1% L-Glutamine  
1% Pen/Strep 
DSMZ:  
ACC 635 
32D Mouse  RPMI 1640 
10% FCS 
1% L-Glutamine 
1% Pen/Strep 
10% (v/v) WEHI3B 
conditioned media 
DSMZ:  
ACC 411 
PLB985 Human acute myeloid leukemia cell 
line (derivative of HL-60) 
RPMI 1640 
10% FCS 
1% L-Glutamine 
1% Pen/Strep 
M. Grez 
DSMZ:  
ACC 139 
XCGD-
PLB985 
Human acute myeloid leukemia cell 
line with a disrupted CYBB gene by 
homologous recombination 
RPMI 1640 
10% FCS 
1% L-Glutamine 
1% Pen/Strep 
M. Grez 
WEHi-3B Mouse myelomonocytic leukemie cell 
line to produce iL3 cytokine  
Iscove basal Medium 
10% FCS 
1% L-Glutamine 
1% Pen/Strep 
0.1% beta-
Mercaptoethanol 
DSMZ:  
ACC 26 
 
2.1.13 Bacterial stains 
Name  Genotype Source 
DH5α F- ϕ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 
hsdR17(rK-,mK+) phoA supE44 thi-1 gyrA96 relA1  
 
TOP 10 E. coli F- mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK 
rpsL (StrR ) endA1 nupG 
Invitrogen 
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2.1.14 Oligonucleotides 
All oligonucleotides were ordered from Sigma Aldrich 
Oligo Sequence (5’-3’) 
Cloning of EGFP sgRNAs 
BH001 g32DG1 s caccgGAGGAACTGTTCACCGGCG 
BH002 g32DG1 as aaacGTGAACAGTTCCTCGCCCTc 
BH003 g32DG2 s caccgGAGGAACTGTTCACCGGCG 
BH004 g32DG2 as aaacCGCCGGTGAACAGTTCCTCc 
BH037 g32DG1.4 s caccgGGGCGAGGAACTGTTTCAC 
BH038 g32DG1.4 as aaacGTGAAACAGTTCCTCGCCCc 
BH039 g32DG1.7 s caccgAAGGGCGAGGAACTGTCAC 
BH040 g32DG1.7 as aaacGTGACAGTTCCTCGCCCTTc 
BH041 g32DG2.3 s caccgGGAACTGTTCACCGCGGCG 
BH042 g32DG2.3 as aaacCGCCGCGGTGAACAGTTCCc 
BH043 g32DG2.5 s caccgCGAGGAACTGTTCACGGCG 
BH044 g32DG2.5 as aaacCGCCGTGAACAGTTCCTCGc 
Cloning of CYBB sgRNAs 
BH137 sgCYBB54 s caccgCAGCACTGGCACTGGCCCA 
BH138 sgCYBB54 as aaacTGGGCCAGTGCCAGTGCTGc 
BH139 sgCYBB173 s caccgGTACCTGGCTGTGACCTGT 
BH140 sgCYBB173 as aacACAGGTCACAGCCAGGTACc 
BH141 sgCYBB45 s caccgTTTACACAAGAAAACGTCT 
BH142 sgCYBB45 as aaacAGACGTTTTCTTGTGTAAAc 
BH143 sgCYBB124 s caccgACATCTATTTAATGTGTAA 
BH144 sgCYBB124 as aaacTTACACATTAAATAGATGTc 
DSA57 sgCYBB-Ex3 s caccgTCAGCACTGGCACTGGCCA 
DSA58 sgCYBB-Ex3 
as 
aaacTGGCCAGTGCCAGTGCTGAc 
DSA60 sgCYBB-Ex6 s caccgTACCTGGCTGTGACCCTGT 
DSA61 sgCYBB-Ex6 
as 
aaacACAGGGTCACAGCCAGGTAc 
  
 
 
Generation of EGFP mutant vectors 
SFHR037 SBmGW s ATGGTGTCCAAGGGCGAGGAACTGTTCACCGCGGCGTGGTGCCCATCCTG 
SFHR038 SBmGW as ATGGGCACCACGCCGCGGTGAACAGTTCCTCGCCCTTGGACACCATGGTT 
SFHR046 SBmGW-K6 s ATGGTGTCCAAGGGCGAGGAACTGTTCACCGTGGTGCCCATCCTG 
SFHR047 SBmGW-K6 as ATGGGCACCACGGTGAACAGTTCCTCGCCCTTGGACACCATGGTT 
SFHR048 SBmGW-K16 s ATGGTGTCCAAGGGCGAGGAACTGTTCACCGCGAGCGTGGTGCCCATCCTG 
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SFHR049 SBmGW-K16 as ATGGGCACCACGCTCGCGGTGAACAGTTCCTCGCCCTTGGACACCATGGTT 
SFHR050 SBmGW-K18 s ATGGTGTCCAAGGGCGAGGAACTGTTCACCGCGGGCGTGGTGCCCATCCTG 
SFHR051 SBmGW-K18 as ATGGGCACCACGCCCGCGGTGAACAGTTCCTCGCCCTTGGACACCATGGTT 
SFHR052 SBmGW-K29 s ATGGTGTCCAAGGGCGAGGAACTGTTCACCGCGGTGCCCATCCTG 
SFHR053 SBmGW-K29 as ATGGGCACCGCGGTGAACAGTTCCTCGCCCTTGGACACCATGGTT 
SFHR054 SBmGW-K33 s ATGGTGTCCAAGGGCGAGGAACTGTTCACCGGCGCGGTGCCCATCCTG 
SFHR055 SBmGW-K33 as ATGGGCACCGCGCCGGTGAACAGTTCCTCGCCCTTGGACACCATGGGT 
Generation of CYBB mutant vectors 
BH111 SB173CW s GGGCGGCCTGTACCTGGCTGTGACCTGTTGGCCGGCATCACCGGCGTG 
BH112 SB173CW as CACGCCGGTGATGCCGGCCAACAGGTCACAGCCAGGTACAGGCCGCCC 
BH113 SB54CW s GCTGCTGGGCTCAGCACTGGCACTGGCCCAGGGCCCCTGCCGCCTGCCTG
AA 
BH114 SB54CW as TTCAGGCAGGCGGCAGGGGCCCTGGGCCAGTGCCAGTGCTGAGCCCAGCA
GC 
BH121 SB124CW s GCGCCATCCACACCATCGCACATCTATTTAATGTGTAATGGTGCGTGAAC
GCCCGGGTG 
BH122 SB124CW as CACCCGGGCGTTCACGCACCATTACACATTAAATAGATGTGCGATGGTGT
GGATGGCGC 
BH123 SB45CW s CGACATCCCCCCCAAGTTCTTTTACACAAGAAAACGTCTTGGCAGCGCCC
TGGCCCTGG 
BH124 SB45CW as CCAGGGCCAGGGCGCTGCCAAGACGTTTTCTTGTGTAAAAGAACTTGGGG
GGGATGTCG 
Shotgun cloning 
AR36 Shotg HPRT s TCCCTTCATAGAGACAAGGAATG 
AR163 Shotg HPRT 
as 
CCTGGGTTCTACCCCAGCACAG 
AR102 Shotg EGFP 
as 
TCATGTGGTCGGGGTATCTG 
SFHR20 Shotg EGFP 
as 
CTTGTACAGCTCGTCCATGC 
SFHR43 Shotg IRES s TCTGTAGCGACCCTTTGCAG 
BH234 Shotg CYBB as AGGATCAGGCACAGGGTGAT 
Surveyor assay 
BH229 Svyr45/54 s TGGCTCTCCTCAAGCGTATT 
BH230 Svyr45/54 as CCATCTTGTGGAAGGTCAGG 
BH231 Svyr173 s CACCTGTTCAACGTGGAGTG 
BH232 Svyr173 as CTCGCACAGGTACAGGAACA 
BH233 Svyr124 s AACGTGTTCCTGTTCGTGTG 
BH234 Svyr124 as AGGATCAGGCACAGGGTGAT 
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2.2 Methods of molecular biology 
2.2.1 Cultivation of bacteria  
Liquid culture 
E.coli (usually DH5α) bacteria were grown in Luria Broth (LB) medium supplemented 
with 100 µg/ml ampicillin (LB-Amp) at 37°C overnight (~16 h) and 220 rpm in a bacteria 
shaker (Roth). 
 
Culture plate 
Bacteria were plated on ampicillin containing LB-agar plats by using an inoculation 
spreader. Plates were incubated overnight at 37 °C in an incubator until bacteria 
colonies were visible (~16 h). Bacteria plates were stored up to 4 weeks at 4°C. 
 
2.2.2 Cloning processes 
Restriction 
For restriction of DNA type II restriction endonucleases were used, which recognize 
specific sites of double stranded DNA sequences (usually 4 – 8 bp) and cleave in the 
sequence. Thereby either blunt or sticky ends are produced. DNA digestions were 
performed using commercially available endonucleases from New England Biolabs 
(NEB) according to the manufacturer’s instructions. For a preparative restriction 1 – 5 
µg and for an analytical restriction 0.2 – 1 µg DNA was used.  
 
Standard digestion: 
0.2 to 5 μg    DNA for analytical or preparative purpose 
0.1 µl volumes   10x reaction buffer (corresponding NEB buffer 1‐4) 
10 U per µg DNA  Restriction enzyme  
add till 0.05 µg/µl DNA ddH2O 
 
The reaction mixture was incubated for 1 – 2 h at 37°C or higher (enzyme dependent). 
In case of a double digest the optimal buffer for the double digest was chosen 
according to the manufacturer’s instructions. 
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Dephosphorylation of 5’–ends of DNA 
The antarctic phosphatase catalyzes the removal of 5´ phosphate groups from DNA 
and RNA. Dephosphorylation was used to minimize self-ligation of the vector 
background in cloning reactions. Since phosphatase‐treated fragments lack the 5´ 
phosphoryl terminus required by ligases, they cannot self‐ligate. The enzyme can be 
added directly into the digestion reaction after DNA digestion. 
 
Standard dephosphorylation: 
50 µl   Restriction mix  
6 µl   Antarctic Phosphatase‐Buffer (10x) 
2 µl   Antarctic Phosphatase  
add 60 µl ddH2O 
 
The reaction was incubated for 30 min at 37°C. 
 
Purification and ligation of vectors and inserts 
Before ligation, the vectors and the inserts were purified with the “DNA Clean & 
Concentrator”-kit (Zymo Research) according to the manufacturer’s instructions. For 
ligation, the T4 DNA ligase was used to catalyze the formation of phosphodiester 
bonds between the fragments under consumption of ATP. The ligation was applied for 
fragments exhibiting complementary overhangs (sticky‐end ligation) or blunt ends 
(blunt‐end ligation). As control sample a reaction which only contains plasmid DNA 
was used. 
 
Standard ligation: 
0.1 – 1.0 µg  total DNA (3:1 to 5:1 Insert:Vector ratio) 
2 µl    10x reaction buffer 
1 µl    T4 DNA ligase 
add 20 µl   ddH2O 
 
The reaction mixture was incubated at RT for a minimum of 2 h before transformation 
into competent bacteria. 
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TA-Cloning 
This easy and fast cloning technique relies on the ligation of the overhang of adenine 
and thymine at the end of different DNA fragment. Shot gun cloning of PCR 
amplification products was performed using the pGEM-T vector system (Promega, 
Mannheim, Germany) according to the manufacturer’s instructions. pGEM-T vector is 
a linearized vector with a single 3´-terminal thymidine at both ends. These compatible 
overhangs for PCR products generated by certain thermostable polymerases (e.g. 
Taq-Polymerase) greatly improve the efficiency of ligation. Positive clones were 
sequenced with a T7 primer. 
 
Standard reaction 
1 – 4 µl  PCR‐reaction 
1 µl  10x reaction buffer  
1 µl  pGEM-T vector 
add 10 μl ddH2O  
The reaction was incubated at RT for 1 h. The reaction was subsequently used for 
transformation in competent bacteria.  
 
Golden Gate Assembly 
Golden Gate assembly exploits the ability of type IIS restriction endonucleases to 
cleave DNA outside of the recognition sequence. Combinations of overhang 
sequences can be assembled using T4 DNA ligase. This one step cloning method 
combines restriction and ligation reaction in one tube (Engler et al. 2008139). 
 
Annealing of the oligonucleotides 
50 pmol of each complementary oligonucleotides were added to 40 µl ddH2O and 
incubated at 98°C for 5 min. Annealing was achieved by cooling down the 
oligonucleotide mixture at RT for 20 min.  
 
Standard oligo annealing 
5 µl  Oligo 1 (100 µM)  
5 µl   Oligo 2 (100 µM)  
40 µl   ddH2O  
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Golden Gate reaction 
150 ng  Vector (LCv2 and derivatives) 
5 µl   Annealed Oligos  
2 µl   10x ligase Buffer 
1 µl   T4 DNA ligase 
1 µl   BsmBI restriction enzyme  
add 20 µl ddH2O 
 
Program 
37°C     5 min 
16°C   10 min 
37°C   15 min 1 cycle 
80°C     5 min 1 cycle 
 4°C     Hold 
 
2.2.3 Transformation of competent bacteria 
Transformation of E. coli (usually DH5α) is the method to amplify plasmid DNA through 
cellular replication. Most of the plasmids are “high copy” plasmids which are amplified 
to multiple copies within the bacteria independent of cellular replication resulting in high 
yields of plasmid DNA. 
 
Chemically competent DH5α cells were thawed on ice and approximately 10 ng DNA 
or 20 µl ligation reaction was added and incubated on ice for 20 min. A heat shock was 
performed by incubation in a water bath at 42°C for 1 min. After additional on ice for 
5 min, cells were plated on agar plates containing ampicillin (100 µg/ml) and incubated 
at 37°C overnight. 
 
 
 
 
 
 
 
10 cycles 
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2.2.4 Plasmid preparation 
Miniprep 
For analytical scale purification of low amounts of DNA (Miniprep), 2 ml LB-Amp 
medium were inoculated with single bacteria clone in a 10 ml tube (Falcon) and grown 
at 37°C overnight. The bacteria were pelleted at RT and 13000 rpm for 5 min in a 
benchtop centrifuge and the supernatant was discarded. The bacteria pellet was 
processed with buffers from the Maxiprep-Kit (Nucleobond PC500 Maxi Kit). In brief, 
the pellet was resuspended in 100 µl S1 buffer, lysed 200 µl S2 buffer for 5 min at RT 
and neutralized using 150 µl S3 buffer. Debris was pelleted at 13000 rpm for 5 min. 
The supernatant was transferred to a fresh tube and the DNA precipitated by addition 
of 1 ml of 100% ethanol. The DNA was pelleted at 13000 rpm for 5min, washed once 
with 150 µl of 70% ethanol (13000 rpm for 5min). The dried pellet was resuspended in 
50 µl ddH2O. 
 
Maxiprep 
For extraction of larger amounts of DNA (Maxiprep) 250 ml LB Amp medium were 
inoculated and cultivated at 37°C overnight in a 1500 ml shake flask. Preparative scale 
plasmid preparation from transformed bacteria was performed using the Nucleobond 
PC500 Maxi Kit (Macherey‐Nagel) according to the manufacturer’s instructions. This 
kit uses an anion-exchange tip where plasmid DNA selectively binds under low‐salt 
and pH conditions. RNA, proteins, metabolites, and other low‐molecular‐weight 
impurities are removed by a medium‐salt wash, and pure plasmid DNA is eluted in 
high‐salt buffer. The DNA is concentrated and desalted by isopropanol precipitation 
and collected by centrifugation. The DNA pellet was dried and dissolved in ddH2O to a 
concentration of 1 µg/µl. The concentration of the isolated plasmid DNA was 
determined photometrically at absorption A260 by NanoDrop (Thermo Fisher Scientific). 
 
2.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis allows the separation of DNA molecules by their size. 
1 - 2% agarose gels were used, the required amount of agarose powder was mixed 
with 1x TAE buffer and dissolved by heating the emulsion in a microwave oven. 0.1 
µg/µl ethidium bromide or 1 µl HDGreen Plus per 20 ml agarose gel was added to the 
dissolved agarose and the gel was casted into a tray. Ethidium bromide / HDGreen 
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Plus intercalates into DNA and visualizes DNA under UV light. Combs with the 
appropriate number and size of teeth were used to make the loadings slots. After 
polymerization, the gel was covered in 1x TAE buffer, samples were mixed with 10x 
loading buffer and loaded onto the gel. 1 kb Plus DNA Ladder was used as marker. 
The DNA fragments were separated by applying 120 V for 30 – 60 min in an 
electrophoresis chamber. The DNA fragments were visualized on a transilluminator 
and documented or extracted from the gel (see below). 
, 
2.2.6 Gel extraction of DNA fragments 
To isolate an appropriate DNA fragment from an agarose gel, the DNA band of interest 
was cut out of the gel under UV light and transferred into a 2 ml micro tube. The DNA 
purification from an agarose gels was performed using the ZymocleanTM Gel DNA 
Recovery Kit (Zymo Research) according to the manufacturer’s instructions. This kit is 
based on binding of DNA to silica based matrixes in the presence of a high 
concentration of chaotropic salt. After washing the agarose to remove impurities the 
pure DNA was eluted using 50 µl of ddH2O. 
 
2.2.7 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a method for oligonucleotide primer directed 
enzymatic amplification of a specific DNA sequence of interest. The DNA polymerase 
amplifies a template DNA bordered on the forward and reverse primer in an 
exponential manner. The polymerase need appropriate buffer, oligonucleotides 
(primers), deoxynucleotides (dNTPs) and cycling conditions. The amplified fragment 
can be used for further molecular biological methods. 
 
Standard PCR-reaction 
10 µl    10x Puffer 
2 µl    10 mM dNTP-Mix 
2.5 µl    Forward Primer (10 µM) 
2.5 µl   Reverse Primer (10 µM) 
50 – 500 ng   Template DNA 
0:5 µl    Q5 High-Fidelity DNA Polymerase 
add 50 µl  ddH2O 
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Standard PCR-protocol 
98°C     2 min     Initial Denaturation 
98°C   20 sec  Denaturation 
50 – 72°C 20 sec  Primer Hybridization 
72°C   30 sec/kb  Elongation 
72°C     2 min   Final Extension 
4°C  ∞   Hold 
 
The optimal primer hybridization temperature was determined by OligoAnalyzer from 
NEB (http://tmcalculator.neb.com/#!/) and in some cases by a temperature gradient. 
Amplificated products were subsequently analyzed by agarose gel electrophoresis 
(2.2.6). 
 
2.2.8 PCR product extraction  
The PCR-product was purified using the DNA Clean & ConcentratorTM -5 (Zymo 
Research) according to the manufacturer’s instructions. This kit is based on binding of 
DNA to silica based matrix in the presence of a high concentration of chaotropic salt. 
After washing off the impurities the pure DNA was eluted using 50 µl of ddH2O. 
 
2.2.9 Nucleic acid sequencing 
Nucleic acid sequencing was performed by Seqlab Company (Göttingen, Germany). 
DNA samples containing approximately 1 μg plasmid or 0.1 µg PCR-product and 
30 pmol sequencing primer in 15 µl total volume were prepared and sent to the 
sequencing service. 
 
2.2.10 Isolation of genomic DNA from cells  
Phenol/Chloroform/Isoamylalkohol (25:24:1) was used for gDNA extraction. Up to 
5x106 cells were centrifuged 5 min at 1200 rpm at RT and the supernatant was 
discarded. The cell pellet was resuspended in 400 µl SDS cell-lysis buffer, containing 
150 µg/ml proteinase K. The cells were incubated at 60°C overnight. Afterwards, 300 µl 
phenol/chloroform/isoamylalkohol were added and the mixture was vortexed and then 
centrifuged (RT, 13000 rpm, 5 min). The aqueous phase containing DNA (upper) was 
25 – 35 Cycles 
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transferred to a new tube and mixed with 300 µl chloroform. Vortexing and 
centrifugation was repeated. The upper phase was transferred to a new tube and 
mixed with 1 ml 100% ethanol (vortexed and centrifuged) for precipitation of the DNA. 
The pellet was washed with 500 µl of 70% ethanol (13000 rpm for 5min at RT). The 
genomic DNA pellet was dried and dissolved in ddH2O to a concentration of 200 ng/µl.  
 
2.2.11 Surveyor Assay 
For the analysis of CYBB indels generated by engineered nucleases, the enzyme 
mismatch cleavage method was used. This method uses enzymes, such as T7E1 or 
Surveyor, that cleave heteroduplex DNA at mismatches and extrahelical loops formed 
by single or multiple nucleotides. In this study, Surveyor® Mutation Detection Kit-S100 
(IDT, Leuven, Belgium) was used. RNG targeted CYBB sites were PCR amplified to 
obtain 500 nt sized products and PCR product were purified using the DNA Clean & 
ConcentratorTM -5 Kit (Zymo Research). For the analysis of on-target mutation rates, 
400 ng of purified PCR product was subjected to the Surveyor assay according to the 
manufacturer’s instructions. PCR products were mixed with 2 μl 10× Taq DNA 
Polymerase PCR buffer and water was added to a final volume of 20 μl. To enable 
heteroduplex formation the DNA was reannealed as follows: 95°C for 10 min, 95°C to 
85°C ramping at −2°C/s, 85°C to 25°C at −0.25°C/s, 25°C for 1 min and hold at 4°C. 
After re-annealing, products were treated with Surveyor nuclease and Surveyor 
enhancer S following the manufacturer's instructions and analyzed on 2% Agarose gel 
(see 2.2.5). Indel percentages derived from Image J plots140 were calculated by 
following formula105:  
100 ∗ (1 − (1 −
𝑏 + 𝑐
𝑎 + 𝑏 + 𝑐
)
0.5
) 
 
Where 𝑎 is the integrated intensity of the undigested PCR product, and 𝑏 and 𝑐 the 
integrated intensities of each cleavage product. 
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2.2.12 Southern Blot 
Southern blot is a technique to detect specific DNA sequences in genomic DNA 
samples. It combines the transfer of electrophoretically separated DNA fragments to a 
nylon membrane and subsequent detection of specific DNA sequences by 
hybridization with radioactively labeled DNA probes.  
 
DNA isolation was performed as described in chapter 2.2.10. 15µg of genomic DNA 
were digested overnight using NcoI restriction enzyme and fragments were resolved 
on a 0.8% agarose gel alongside a DNA size standard. The gel was stained for 30min 
in 1x TAE + EtBr and a picture was taken for later size identification of visualized DNA 
fragments. The gel was destained in depurination solution (0.25 M HCl) for 15 min and 
rinsed in water. Thereafter, the gel was neutralized in alkaline transfer buffer (0.5 M 
NaOH, 1.5 M NaCl) for 30 min and an alkaline transfer was set up for the transfer of 
the DNA fragments onto a Nytran SPC membrane (Whatman, Maidstone, UK). 
Therefore, a pack of disposable paper towels was set up as a suction reservoir. On top 
of this pack two Whatman layers were placed with the same size as the gel on which 
the membrane was mounted. The gel was directly placed onto the membrane avoiding 
air bubbles. The whole transfer set-up was covered with plastic wrap, the gel was 
weighted with a plastic plate and a bottle with approx. 500ml of water. Transfer was 
performed over 48h. After transfer, the blot set-up was broken down carefully, 
discarding all paper towels, Whatman paper and the dried gel. The membrane was 
neutralized for 15min in 0.5M Tris/HCl pH 7.5, 1.5 M NaCl and equilibrated for 
hybridization in 2xSSC (saline sodium citrate buffer). Radioactive labelling of the BFP 
probe was carried out using the RediPrime II DNA Labeling System (Amersham) 
according to the manufacturer’s protocol. Hybridization was performed using 
ExpressHyb Hybridyzation Solution (Clontech) according to the manufacturer’s 
protocol. The membrane was washed twice at 37°C with 2xSSC, 0.1% SDS and twice 
with 0.5xSSC, 0.1% SDS. Signals were detected using overnight exposure of Kodak 
BioMax MS films at -80°C using amplifier screens. 
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2.2.13 Western Blot  
Western blot is a technique to detect specific proteins from a complex mixture of 
proteins extracted from cells. The technique is based on four elements: separation 
protein by size, protein transfer to a membrane and target protein with specific 
antibodies and detection of the specific signals. 
 
Cell lysis to extract protein: 
Cells were harvested by centrifugation at RT and 1200 rpm for 5 min and the 
supernatant was discarded. The cell pellet was washed once with 1xPBS and the pellet 
was lysed in SDS-lysis buffer (75 – 250 µl) supplemented with Protease Inhibitor 
Cocktail (Roche, Mannheim, Germany) on ice for 30 min. The cells were then 
sonicated twice for 30 sec, (5x, 45% power) and transfer to ice. The cool lysates 
mixture was centrifuged at 4ºC and 15000 rpm for 3 min. The supernatant was 
transferred to a new 1.5 ml tube. 
Protein concentration was determined using the Lowry protein assay. To measure 
protein concentration, 1 – 5 µl sample or protein standard was mixed with 200 µl Lowry 
solution A, filled up to 1 ml with Lowry solution B, mixed by vortexing and samples were 
measured at the absorbance 595 nm. The samples with equal protein concentrations 
were resuspended in 4x loading buffer containing 20% beta-mercaptoethanol, boiled 
at 95C for 5 min and stored at 20°C. 
 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transfer: 
The proteins were separated by SDS-PAGE. Equal volumes of protein lysates were 
loaded onto a polyacrylamide gel (stacking gel: 4% acrylamide, separating gel: 10% 
acrylamide) together with 1 µl protein standard. The gel was run in MOPS buffer, 
starting with 80 V for 10 min and then increased voltage to 160 V for 1h  
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Component 4% Stacking gel  10% Separating gel 
Acrylamide 40% 687 µl 1500 µl 
Bis-Tris Buffer 550 µl 1730 µl 
ddH2O 2720 µl 2800 µl 
APS 10% 40.3 µl 40 µl 
TEMED 4 µl 11.2 µl 
 
After separation by SDS-PAGE, western blot were blotted via electrophoresis onto a 
nitrocellulose membrane using the wet blot method. The membrane and 2 filter papers 
were cut to gel size. Membrane, filter paper and blotting pads were soaked in pre-
cooled (4°C) transfer buffer. Blotting pads were placed on cathode, on topped with a 
filter paper, the gel was removed from the electrophoresis apparatus and placed on 
top, before membrane, another filter paper and more blotting pad were placed. After 
each layer roll out any air bubbles. The transfer was carried out in transfer buffer at 
35 V and 500 mA for 2 h.  
 
Immunostaining of blotted proteins and detection: 
To get a first impression of the quality of the transfer and the equality of protein loading, 
an unspecific protein staining with ponceau-red was performed. The membrane was 
blocked with 5% milk in TBS-T at RT for 1h, before incubated with a target protein 
specific primary antibody on a shaker at 4°C overnight. On the next day the membrane 
was washed 3 times for 5 min with TBS-T and the secondary antibody was added at 
RT for 1 h. Before detection, the membrane was washed again 3 times with TBS-T. 
The ECL-substrate for horseradish peroxidase was applied to the membrane 
according to manufacturer`s instructions and detection was performed with the 
Odyssey FC device. 
 
Mouse monoclonal antibody against GFP was purchased from Roche and rabbit 
monoclonal antibody against GAPDH was purchased from Cell Signaling (Frankfurt 
am Main, Germany). Monoclonal anti-human CYBB antibody (moAB48) was obtained 
from LifeSpan BioSciences (Seattle, WA, USA). 
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2.3 Cell culture and virological methods 
2.3.1 Cultivation of cell lines  
Cell lines were cultivated in the appropriate medium in an incubator at 37°C, 5.0% CO2 
in a saturated water atmosphere and were passaged twice a week. Hematopoietic 
(Suspension) cells were grown in RPMI-1640 medium supplemented with 10% (v/v) 
heat-inactivated fetal calf serum (FCS), 2 mM glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin. Hematopoietic 32D cell cultures were supplemented further with 
10% (v/v) WEHI-3B conditioned medium. WEHI-3B cells were grown in IMDM 
supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), 2 mM glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin, 0,1% beta-mercaptoethanol. For 
splitting the cells were washed with 1xPBS by centrifugation (at 1200 rpm, 5 min) and 
an appropriate cell number was resuspended in fresh media. 
 
The adherent HEK293T cells were grown in DMEM medium supplemented with 10% 
FCS (v/v), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells 
were grown until a confluence of 80 – 90% was reached and then split by washing 
once with PBS and detaching with Trypsin‐EDTA before an appropriate fraction of the 
resulting suspension was seeded into a new culture flask with fresh medium. 
 
2.3.2 Cell counting and determination of cell viability 
Cell number and viability were controlled by trypan-blue exclusion. To count the cells 
10 – 50 µl cell suspension was mixed with an equal volume of trypan-blue solution. 
Trypan-blue selectively stains dead cells as it is not able to pass through intact cellular 
membranes. 10 µl of the mixture was applied to a counting chamber and only 
unstained cells were counted. Cell number were calculated according to this formula: 
 
𝐶𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟/𝑚𝑙 =
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∗ 104 
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2.3.3 Make WEHI-3B conditioned media 
WEHI-3B cells were expanded in 150-cm2 flasks to a density of 80% to 90% 
confluence. The cells were collected, centrifuge (at 1200 rpm and 5 min) and washed 
once with 1xPBS (at 1200 rpm, 5 min). The cell pellet divided to four 150-cm2 tissue 
culture flasks, each with a total volume of 150 ml of growth medium. During the 
expansion stage, the pH indicator in the conditioned medium might have become 
yellowish in color. 90% conditioned medium was collected every 2 – 3 days and filtered 
through a 0.22 μm filter. Fresh medium was added to the remaining cells. Filtered 
conditioned medium was collected in sterile 50-ml conical tubes in 50-ml aliquots to 
and stored at –20°C. 
 
2.3.4 Freezing and thawing of cultured cell 
Freezing 
To freeze cells, adherent cells were first washed once with PBS, detached through 
trypsinising, resuspended in the appropriate medium and then like suspension cells, 
centrifuged (1200 rpm, 5 min) to pellet the cells. The cell pellet was washed with 
1xPBS, resuspended in freezing medium (90% FCS, 10% DMSO) to reach 5x106 cells 
per 1 ml, transferred to cryotubes in 1 ml aliquots and frozen in a freezing container at 
‐80°C. After 3 days the cells were transferred into liquid nitrogen. 
 
Thawing 
Cryotubes were quickly placed at 37ºC until the suspension was almost thawed. 
Immediately, the cells were transferred into a 50 ml falcon tube with 24 ml prewarmed 
medium. The cells were centrifuged at 1.200 rpm for 5min to remove the cytotoxic 
DMSO. Lastly the cells were resuspended in fresh medium and seeded into 
appropriate culture flasks. 24 h later the medium was exchanged to fresh medium. 
 
2.3.5 Nucleofection 
Nucleofection is an electroporation-based transfection technique. Electroporation is a 
biophysical method in which the cell membrane becomes permeable by applying 
pulsed electric fields across a cell. This allows chemicals, protein or DNA to be 
introduced into the cells. The nucleofection technology is carried out with cell type 
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specific electrical parameters, generated by a device called Nucleofector and with cell-
type specific solutions. 
 
For nucleofection of 32D cells, 1 x 106 cells were washed twice in 1xPBS, resuspended 
in nucleofection buffer and nucleofected with 1 µg donor plasmid, 0.5 µg of each Hprt-
TALEN or 0.4 µg hspCas9 and 1.6 µg of sgRNA expression vector (Amaxa 
nucleofector kit V with E-32 program, Amaxa Biosystems, Cologne, Germany) 
according to the manufacturer’s protocol. The cells were selected in growth medium 
containing either 2 µg/ml 6-thioguanin (6-TG) (Sigma-Aldrich, Taufkirchen, Germany) 
or 1 x hypoxanthine-aminopterin-thymidine (HAT) (Life technologies, Darmstadt, 
Germany). 
 
2.3.6 Lentiviral vector production 
Lentiviral supernatants were produced by polyethylenimine (PEI) based transient co-
transfection of HEK-293T cells. Briefly, transfer vector, lentiviral gag/pol helper 
plasmids for integration (pCMV8.91) or integrase-defective (pCMV8.74) variants and 
envelope plasmid encoding the glycoprotein of vesicular stomatitis virus (VSV-G) 
(pMD2.G, Addgene #12259) were transfected at a molar ratio of 3:1:1 by standard PEI 
transfection. 24 h prior to transfection, HEK 293T cells were seeded at 1.2x107 per 
14.5 cm plate in 16.5 ml DMEM with 10% FCS (v/v), 2 mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin to have a confluence 75-85% at the time of 
transfection. At the day of transfection: 
 
Prepare DNA solution in a 14 ml tube for every plate: 
14 µg   psPAX2 (gag, pol) 
8 µg   pMD2.G (vsvg) 
16 µg   Transfer DNA 
1.75 ml  DMEM w/o supplements 
 
Prepare PEI solution in a 14 ml tube for every plate 
171 µl  PEI (1 µg/µl PEI  4.5 µl per 1 µg DNA)   
1.75 ml  DMEM w/o supplements  
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After 12 – 16 h the medium was replaced with 11 ml fresh medium. A maximum of 
33 ml per viral supernatant could be used which was routinely collected from three 
14.5cm dishes. After another 48 h viral supernatants were harvested, the supernatants 
of the same viral vector were pooled, sterile filtered (0.45 µm pore-size PVDF-
membrane filter; Millipore, Schwalbach, Germany) and concentrated (100-fold) by 
ultracentrifugation. The virus was underplayed with 5 ml of a sucrose (20% v/v sucrose 
in PBS) and centrifuged (50,000 g, 2:20 h, 4°C). Pelleted viral particles were 
resuspended in 330 µl StemSpan SFEM serum-free medium (StemCell Technologies, 
Grenoble, France) without any supplements at 4°C overnight and stored at −80°C in 
50 µl aliquots.  
 
2.3.7 Titration of vector particles 
Several different methods for titration of viral supernatants exist. In the present study 
two different methods were used.  
 
For integrated lentivirus, which expresses a virus encoded surface transgene in target 
cells, the functional titer was determined by serial dilutions of viral supernatant 
transducted of XCGD‐PLB985 cells followed by flow cytometry 3 days post-
transduction. The number of cells expressing the vector‐encoded transgene (CYBB or 
TagBFP/EGFP) directly correlates with the number of functional vector particles in the 
supernatant and can therefore be calculated. For the titration of virus, 2x105 XCGD‐
PLB985 cells were seeded into a single well of a 24well plate. The lentiviral suspension 
was serially diluted in 1:10 steps with medium supplemented with 8 µg/ml polybrene 
as a chemical transduction enhancer and applied to the wells to a final volume of 500μl 
medium. After incubation overnight, media was removed and 1 ml fresh medium was 
added. Cells were grown for 3 days before analysis of the percentage of positive cells 
by flow cytometry. For CYBB, a FITC labelled Anti-Flavocytochrome b 558 monoclonal 
antibody which recognizes an external epitope of CYBB (7D5-FITC141) was used. For 
vector titer calculation, dilutions, that contained about 5 ‐ 20% of transduced cells, was 
chosen.  
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Calculation of virus titer: 
 
Titer [
TU
ml
] = (
number of seeded cells ∗  dilution factor ∗ positive cells [%]
100 [%]
) / 0.5 ml 
 
To determine IDLV titers, p24 viral coat protein concentrations were estimated in the 
viral supernatants using the p24 ELISA kit from INNOTEST (Fujirebio, Hannover, 
Germany) according to the manufacturer’s instructions. To determine the number of 
particles corresponding to every picogram of p24 antigen, we used a conversion factor 
of 6.12 x 103 particles/pg derived from the flow cytometric analysis of PLB cells 48 h 
after SBmGW-IDLV transduction.  
 
2.3.8 Flow cytometry and cell sorting  
Flow cytometry, also referred as Fluorescence Activated Cell Sorting (FACS), is a 
biophysical technique for biomarker detection. An appropriate amount of cells (0.1‐
1x106) from a cell culture were transferred to 5 ml polystyrol‐FACS‐tubes. The tubes 
were filled to the top with PBS and centrifuged at 1200 rpm for 5 min. The supernatant 
was removed, the cells were resuspended in 200 µl PBS and ready for measurements 
or staining. For cell surface antigen staining, cells were incubated with conjugated 
antibodies (1 µl of each antibody) in dark, at RT for 20 – 30 min. Then, one wash step 
was performed with PBS to remove unbound antibodies. For the FACS measurement 
the cells were kept in 200 µl PBS. Data acquisition was performed with a BD 
LSRFortessa flow cytometer (BD Biosciences, Heidelberg, Germany). Data was 
analyzed with BD FACSDiva software (BD Biosciences, Heidelberg, Germany) or 
flowing software 2.5.1. Cell sorting was performed in a BD FACSAria III flow cytometer 
(BD Biosciences, Heidelberg, Germany). 
 
2.3.9 Dihydrorhodamine 123 (DHR) reduction assay  
The Dihydrorhodamine 123 (DHR) ‐assay is used to detect superoxide molecules 
generated by the NADPH‐oxidase complex. It is a functional assay of the NADPH 
oxidase and can be used to investigate reconstitution of CYBB repair. The assay relies 
on the conversion of non‐fluorescent DHR123 to highly fluorescent Rhodamine123 
preferentially but not exclusively by superoxide. In addition to superoxide, its 
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derivatives, such as hydroxyl anions or peroxide can also convert DHR, albeit to a 
lesser extent. Activation of NADPH‐oxidase complex in target cells is triggered by the 
addition of the unspecific PKC‐activator PMA (Phorbol 12‐myristate 13‐acetate). 
 
DHR assays were performed as described by Brendel et al 2014142. For granulocytic 
differentiation, PLB-985 and its derivatives were plated in RPMI 1640 supplemented 
with 2.5% heat inactivated FCS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin and 1.25% dimethyl sulfoxide (DMSO) at a concentration of 
2x105 cells/ml for at least 7 days. Flow cytometry was performed to ensure the 
differentiation of labelled cells with anti-CD11b+ antibody. For estimating ROS 
production, the differentiated cells were suspended in 1 ml pre-warmed HBSS (Life 
technologies, Darmstadt, Germany) supplemented with 7.5 mmol/l D-Glucose, 0.5% 
bovine serum albumin (BSA; Sigma-Aldrich) 2000 U/ml catalase (Sigma-Aldrich) and 
5 µg/ml DHR123 (Sigma-Aldrich). Following incubation at 37°C for 10 min, cells were 
exposed to 0.1 µmol/l PMA (Sigma-Aldrich) for 15 min and placed on ice. 
Rhodamin123 fluorescence was measured in a flow cytometer within the next 30 min.  
 
2.3.10 Statistical analysis 
For statistical comparisons between groups, Student´s t-test or one-way analysis of 
variance (ANOVA) with Bonferoni post-hoc test were used as appropriate in 
conjunction with GraphPad Prism 5 software.  
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3. Results  
3.1 Genome editing by homology-directed repair (HDR) versus non-
homologous end joining (NHEJ)  
In an initial project aimed at testing the efficacy of genome editing in hematopoietic 
cells, Transcription activator like effectors nucleases (TALENs) were used. Two 
TALENs were designed directed against 16 nucleotide (nt) stretches on both strands 
of the 3rd murine Hprt exon encoding for the active centrum of hypoxanthine-guanine 
phosphoribosyltransferase (Hprt) enzyme. The Hprt-TALENs were separated from 
each other by a 15 nt spacer (Figure 10A). 32D cells (murine hematopoietic, immature, 
myeloid cell line) were nucleofected with Hprt-TALENs and EGFP encoding donor 
constructs. The nuclefected 32D cells were selected against Hprt expression in 6-
thioguanine (6-TG) containing medium. Less than 5% of the 6-TG resistant cells 
expressed EGFP from the knock-in donor construct (Figure 10B), suggesting that in 
the majority of cells Hprt inactivation was caused by indels associated with NHEJ-
directed DSB-repair.  
To confirm this, individual 6-TG resistant clones were isolated by limiting dilution. The 
mutant Hprt alleles in clones were characterized by genomic PCR and sequencing. 
Consistent with NHEJ, the Hprt open reading frame (ORF) was disrupted by indels of 
different sizes (Figure 10C). 
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3.2 Reconstitution of a point mutated Hprt gene by genome editing 
in murine hematopoietic (32D) cells 
As shown in Figure 10C, modifications induced by NHEJ typically consist small 
deletions or insertions (indels) of variable length of which theoretically about one-third 
should restore the ORF disrupted by a disease mutation (Figure 11). This could lead 
to many ORF reconstitutions, of which some, depending on the position and type of 
the original mutation, should completely or partially recover protein function. 
 
 
 
 
 
 
 
Figure 10: TALEN-assisted Hprt gene editing 
A. Schematic illustration of exon 3 of Hprt gene with TALEN target sequence (highlighted in 
yellow) and EGFP encoding Hprt-targeting (donor) construct. B. Flow cytometry of 6-TG resistant 
32D. Note that less than 5% of the 6-TG cells underwent HDR, suggesting a NHEJ/HDR ratio of 
19/1. C. Indel sequences recovered from 6-TG resistant subclones. 
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To test this prediction, the 32D-C9 subclone (Figure 10C), harbouring a frameshift 
mutation in the active center of Hprt, was nuclefected with the same Hprt-TALENs. 
After positive selection in hypoxanthine-aminopterin-thymidine (HAT) medium, HAT-
resistant cells were obtained, suggesting functional Hprt reconstitution. Genomic PCR 
and sequencing proved that the HAT resistant cells originated from two independent 
clones: one with a synonymous substitution restoring the Ala50 codon and the other 
with Arg51 to Gly codon (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Analysis of INDEL distribution 
Plot depicting frequency of ~750 indels evoked by designer endonucleases from different 
publications. If one postulates that one third of indels between -15 and +5 nt could reconstitute 
the reading frame of a mutated gene, in approximately 25% of all targeted cells expression of the 
gene will be restored. Note: 92% of all indels are between -40 - +40 nt. 
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3.3 NHEJ-mediated reconstitution of a mutated EGFP reporter gene 
in 32D cells  
To determine the efficiency of gene repair by NHEJ, 32D cells that underwent HDR 
after Hprt-TALEN and EGFP donor treatment (32D-EGFP+) were first enriched by 
fluorescence activated cell sorting (FACS) (Figure 10B & Figure 13A).  
Using RNA-guided CRISPR/Cas9 endonuclease (RGN) technology, EGFP 
inactivating (knock-out) mutations were induced in 32D-GFP+ cells using two different 
single guide RNAs (sgRNAs) directed against the N-terminus of EGFP (Figure 13B). 
Expression of sgRNA1 (G1) or sgRNA2 (G2) plus spCas9 in 32D-GFP+ cells 
inactivated EGFP in 17.2% (32DG1) and 22.3% (32DG2) cells, respectively (Figure 
13C).  
 
 
 
 
 
 
 
Figure 12: TALEN-assisted random Hprt gene repair 
Indel sequences recovered from HAT resistant 32D-C9 subclone after nucleofection with Hprt-
TALENs and followed by selection in HAT medium.   
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Next, ten single cell clones from sorted EGFP negative 32DG1 and 32DG2 cells were 
isolated by limiting dilution and their genomic DNA subjected to PCR using Hprt and 
EGFP specific primers (Figure 13B). As shown in Figure 14A, seven of the 32DG1- 
and six of the 32DG2-DNAs yielded amplification products of the expected size. The 
other clones either lacked the entire target sequence (32DG1.5 and 32DG2.9) or the 
generated product was significantly smaller than the expected size (32G1.10, 32DG2.2 
and 32DG2.6), suggesting larger deletions (Figure 14A). To characterize the EGFP 
inactivating indels, PCR products of the expected size were sequenced (Figure 14B). 
 
Figure 13: EGFP mutagenesis in 32D-GFP+ cells 
A. FACS enrichment of 32D cells expressing EGFP from the Hprt locus. B. sgRNAs directed against 
EGFP. C. Frequency of EGFP inactivation in 32D-GFP+ cells after conuclefecting the sgRNAs and 
Cas9 expression constructs. 
  Results 
65 
 
 
 
Next, sgRNAs targeting the 32DG1.4 (+1 nt), 32DG1.7 (-1 nt), 32DG2.3 (+2 nt) and 
32DG2.5 (-1 nt) mutations (Figure 14B) were nuclefected along with spCas9 into the 
respective clones. Consistent with previous genome editing protocols involving 
transfection, gene repair efficiency was low, ranging from 2.3% to 5.5% (Figure 15A). 
 
 
 
 
 
 
 
 
 
Figure 14: Indels induced by NHEJ in 32D-GFP negative cells enriched by FACS and 
subcloned by limiting dilution 
A. EGFP PCR products (see Figure 2B) from 32D-GFP-subclones. B. Sequence analysis of the 
indels recovered by PCR. 
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To determine the type of the secondary indels leading to EGFP repair, genomic EGFP 
amplification products from EGFP+ cells of four FACS sorted 32DG clones (Figure 
15A), were shot-gun cloned into the pGEM-T vector. Eight bacterial clones obtained 
after pGEM-T transformation of E. coli were isolated and sequenced from each clone. 
Figure 15B shows that in most cases the original EGFP reading frame was 
reconstituted by either frame-shifting nucleotide deletions (clones 32DG1.4 and 
32DG2.5) or by frame-reconstituting nucleotide insertions (clones 32DG1.7 and 
32DG2.3). However, in two instances the ORF was reconstituted by one nucleotide 
insertion next to the frame-shifting nucleotide (32DG1.4_3) or by one nucleotide 
insertion upstream of two frame-shifting nucleotides (32DG2.3_1 and 32DG2.3_4) 
 
Figure 15: EGFP repair frequency in selected 32DG subclones 
A. FACS and sort analysis of EGFP repair in the 32DG subclones. B. Indels recovered from individual 
subclones after sorting for EGFP expression.  
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resulting in synonymous substitution and amino acid acquisition, respectively (Figure 
15B).  
 
3.4 NHEJ mediated reconstitution of a mutated EGFP reporter 
transgene in PLB-985 human promyelocytic leukemia cells  
To test the NHEJ gene repair strategy in human cells, PLB985 cells expressing blue 
fluorescent protein (TagBFP) along with either intact (EGFP) or mutationally 
inactivated EGFP (mEGFP) were generated. For this, TagBFP was linked to EGFP or 
mEGFP by an internal ribosomal entry site (IRES). TagBFP-IRES-EGFP cassettes 
were cloned into self-inactivating (SIN) lentiviral vector downstream of an internal 
SFFV promoter (Figure 16A). The mEGFP mutation used in the lentiviral construct was 
identical to the 32DG2.3 indel (Figure 14B), which creates a SacII restriction site by a 
2-nt insertion (Figure 16A). Two lentiviral vectors referred to as SBGW and SBmGW 
(Figure 16A) were used to infect PLB cells at low multiplicity of infections (MOI) to 
obtain single copy integrations. 
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Two days after infection, the transduced PLBs were analyzed by FACS. As expected, 
the majority of SBGW transduced PLBs (SBGW-PLBs) were double positive for 
TagBFP and EGFP (TagBFP+EGFP+) whereas consistent with EGFP inactivation 
SBmGW transduced PLBs (SBmGW-PLBs) expressed only TagBFP (TagBFP+EGFP-) 
(Figure 16B). Transduction efficiency was 2.4% and 1.6% by SBGW and SBmGW, 
respectively. The SBmGW transduced cells were then sorted for TagBFP expression. 
To analyze SBmGW integration copy number, 11 TagBFP+ SBmGW-PLB clones were 
isolated by limiting dilution and examined by Southern blotting. As shown in Figure 17C 
all clones exhibited single copy integrations. 
 
 
 
 
 
Figure 16: Generation of PLB-985 cells expressing dual color reporter transgenes 
A. Lentiviral reporter constructs with cDNAs encoding blue fluorescent protein (TagBFP) and either 
wild type- (SBGW) or mutated (SBmGW) EGFP. B. FACS analysis of transduced PLB cells show 
that 2.4% of SBGW and 1.6% of SBmGW were transduct. Note: Only SBGW-PLB cells represent 
BFP/GFP double positive cells.  
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Next, sgRNA targeting the EGFP mutation (Figure 18A) were cloned into 
pLentiCRISPRv2 lentiviral vector143. The construct was used to infect FACS sorted 
TagBFP+ SBmGW-PLBs by integration defective lentiviruses referred to as IDLV-LC-
sgEGFP2.3 (Figure 18A). As shown in Figure 18B, infection of TagBFP+ SBmGW-
PLBs with LC-sgEGFP2.3 reconstituted EGFP expression in up to 24% of the cells as 
early as 4 days after infection. Moreover, the fraction of TagBFP+EGFP+ SBmGW-
PLBs slightly increased with the time in tissue culture up to 27%, indicating that EGFP 
repair is stable (Figure 18B). This was confirmed by Western blot showing EGFP 
expression in SBmGW-PLBs (Figure 18C).   
 
Figure 17: Single copy 
integration of SBmGW 
lentiviruses in PLB cells 
A. FACS analyis of 11 
TagBFP+ SBmGW-PBL 
clones obtained by limited 
dilutions. B. reporter 
constructs with NcoI site.  
C. Southern blot analysis of 
the clones. NcoI restriction 
fragments of genomic DNAs 
of individual clones were 
resolved by agarose gel 
electrophoresis, transferred 
onto nylon mebranes and 
hybridized to a 32P-labeld 
TagBFP probe. 
  Results 
70 
 
 
 
 
 
 
 
Figure 18: EGFP repair efficiency in PLB-985 cells expressing dual color reporters 
A. Schematic representation of the LC-sgEGFP2.3 lentiviral vector with its target sequence. B. 
Precentege of EGFP positive cells among FACS sorted BFP+ SBmGW PLB cells before and after 
infection with integrase deficient (IDLV) LC-sgEGFP2.3 lentivirus. C. Western blot showing EGFP 
expression in WT-, unsorted SBGW-PBL control cells and in sorted TagBFP+ SBmGW-PLB cells 
before and after IDLV infection. D. SacII restriction fragments of genomic EGFP amplification 
products from SBmGW-PLB cells before and after IDLV treatment. Numbers at the bottom represent 
the amount of uncut DNA estimated by densitometry. 
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To estimate the on-target mutation rate of LC-sgEGFP2.3, genomic EGFP 
amplification products from the transduced SBmGW-PLBs were digested with SacII 
restriction enzyme. Following restriction fragment separation on agarose gels the 
uncleaved DNA was quantified by densitometry using Quantity One 1-D analysis 
software (Bio-Rad). As shown in Figure 18D, up to 87% of the EGFP alleles lost the 
SacII restriction site, which is consistent with a high IDLV-transduction rate. However, 
this on-target mutation rate is likely an underestimate as several indels recovered by 
shot gun cloning regenerated the SacII restriction site (Figure 19A). In combination 
with the 27% EGFP repair rate determined by FACS (Figure 18B), the indel frequency 
suggests that nearly every third indel restored EGFP function.  
 
To investigate this in more detail, genomic EGFP amplification products were shot-gun 
cloned into pGEM-T vector as described above. Sequence analysis of bacterial clones 
revealed that 13 out of 28 cloned indels (46%) restored the ORF. Four of these were 
two nucleotide deletions (Figure 19A, C2, C23, C33 and C34) of which three restored 
the wild type sequence, whereas one (C33) converted Val codon into Ala (Figure 19A). 
The other restored ORFs included amino acid substitutions combined with acquisitions 
and induced by one nucleotide insertions (Gly to Ala and Ser in C16 and C23 or Gly to 
Ala and Gly in C18) or amino acid deletions and substitutions induced by 5 nucleotide 
deletions (Gly deletion in C6 and C22 or Gly + Val deletion substituted by Ala in C29) 
(Figure 19A). Importantly, none of the recovered sequences matched the original 
SBmGW sequence, suggesting an on-target mutation rate of 100%. 
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To test whether the non-canonically reconstituted ORFs are compatible with EGFP 
function, the respective ORFs were replicated in SBGW vector by site-specific 
mutagenesis and individually transfected into HEK293T cells. FACS analysis revealed 
that the C16, C18 and C33 mutations were compatible with EGFP function whereas 
C6 and C29 were not (Figure 19B). Overall, 25% of the indels (7 out of 28) restored 
EGFP function (Figure 19B), which is similar to the fraction of EGFP positive cells 
recovered from the LC-sgEGFP2.3 transduced SBmGW-PLB cells (Figure 18B). 
 
 
Figure 19: mEGFP alleles in 
IDLV infected SBmGW-PLB 
cells 
A. Indel sequences recovered by 
shot-gun cloning. Reconstituted 
SacII restriction sites are 
underlined. B. FACS analysis of 
HEK293T cells expressing 
mEGFP cDNAs reconstituted by 
non-canonical ORFs. 
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3.5 Reconstitution of point mutated CYBB gene expressed in X-CGD-
PLB leukemia cells  
To test whether the donor template free IDLV-RGN strategy would also effectively 
correct bon fide disease mutations, the EGFP in the SBGW vector was replaced with 
either wild type- or mutated CYBB cDNAs. The CYBB mutations were selected from 
the X-CGD patient specific mutation database (CYBBbase variation browser; 
http://structure.bmc.lu.se/idbase/CYBBbase). Altogether, 5 TagBFP-IRES-CYBB 
lentiviral vectors were generated carrying either wild type CYBB (SBwtCW) or one of 
the following point mutations: frameshift-R54fsCYBB (SB54CW), frameshift-
R173fsCYBB (SB173CW), nonsense-E124XCYBB (SB124CW) or missense-
L45RCYBB (SB45CW). 
 
Table 6: Selected CYBB disease mutations and nucleotide sequences of the CYBB-targeting 
sgRNAs 
Mutation Mutation type DNA change Protein 
alteration 
Accession 
number 
sgRNA sequence 
SB54CW frameshift 
(duplication ) 
c.159dupC p.R54fs A53X102  CAGCACTGGCACTGGCCCAGGG 
SB173CW frameshift 
(deletion) 
c.517delC p.L173fs L173X188  GTACCTGGCTGTGACC-TGTTGG 
SB45CW missense c.134T>G p.L45R L45R  TTTACACAAGAAAACGTCTTGG 
SB124CW nonsense c.370G>T p.E124X E124X  ACATCTATTTAATGTGTAATGG 
 
As described for SBGW and SBmGW, wild-type and mutant CYBB carrying 
lentiviruses were transduced into CYBB null PLB985 cells (XCGD cells)144 by low MOI 
infection to obtain single copy integrations. Two days post infection, the transduced 
XCGD cells were analyzed for TagBFP and CYBB expression by flow cytometry. As 
expected, the majority of SBwtCW transduced XCGD cells (XCGD-SBwtCW) 
expressed both TagBFP and CYBB whereas all XCGD cells carrying mutant copies 
(XCGD-SB45CW, XCGD-SB54CW, XCGD-SB124CW and XCGD-SB173CW) 
expressed only TagBFP (Figure 20). This was confirmed in FACS sorted TagBFP+ 
cells Western blot. 
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While SBwtCW expressed both glycosylated and non-glycosylated CYBB, CYBB 
expression was abolished in SB54CW, SB124CW and SB173CW XCGD cells. 
Interestingly, cells carrying the missense SB45CW mutation expressed only the non-
glycosylated CYBB (Figure 21).  
 
 
 
 
 
 
Figure 20: FACS profiles of XCGD cells expressing wild-type and mutant CYBB cDNAs 
A. Lentiviral reporter constructs with cDNAs encoding TagBFP and either wild type- (SBwtCW) or 
mutated (SBmCW) CYBB. B. FACS profiles of PLB985-XCGD cells expressing wild-type or mutant 
CYBB. Note that only XCGD-SBwtCW cells are double positive for TagBFP and CYBB. 
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Next, sgRNAs targeting different CYBB mutations (Table 6) were cloned into 
pLentiCRISPRv2ΔPuro and used to infect FACS-sorted, TagBFP positive XCGD cells 
with corresponding LC-sgCYBB IDLVs. After 14 days, up to 10% of XCGD-SB54CW- 
and XCGD-SB173CW cells stained positive for CYBB (TagBFP+CYBB+; Figure 22A 
&C). Although repair efficiency was only half of that achieved for mEGFP in SBmGW-
PLB cells (Figure 18C), so was the on-target mutation rate estimated, by the Surveyor 
assay (Figure 22C). However, less than 2% of XCGD-SB124CW and XCGD-SB45CW 
cells stained positive for CYBB  
 
 
 
 
Figure 21: CYBB protein expression in XCGD-SBwtCW and SBmCW cells detected by 
Western blot 
No CYBB expression could be detected in the PLB985-XCGD and the cells with mutated CYBB. 
Only the cells carrying the missense mutation in CYBB (SB45CW) express non-glycosylated CYBB. 
XCGD-SBwtCW control cells express both glycosylated and non-glycosylated CYBB. 
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Figure 22 Repair of CYBB mutations in XCGD-PLB cells 
A. FACS profiles of sorted TagBFP+ XCGD cells after IDLV transduction (MOI 11) and staining 
with the monoclonal 7D5 anti-human CYBB antibody. B. Frequency of CYBB positive cells 
amongst TagBFP+ XCGD cells after IDLV treatment. Results are represented as means ± SD of 
3 independent experiments. C. Surveyor assay of CYBB PCR products derived from IDLV treated 
XCGD cells. Indel frequency was calculated according to the formula published by Hsu et al. 
2013.105. 
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To characterize indels compatible with CYBB expression, two different methods were 
used. The first one involved shot-gun cloning of CYBB amplification products from 
sorted, CYBB+ XCGD-SB45CW, XCGD-SB54CW- and XCGD-SB173CW cells (Figure 
23) into pGEM-T followed by sequencing as described in section 4.4. The second 
involved the indel characterization in individual clones isolated by limiting dilution. As 
anticipated, the majority of indels isolated from the XCGD-SB45CW, XCGD-SB54CW 
and XCGD-SB173CW cells contained open reading frames (Table 7, Figure 24 & 
Figure 25).  
In 22 out of 26 XCGD-SB45CW clones, the wild type CYBB sequence was 
reconstituted, one clone had a Lys 44 deletion and rest missense mutations of Arg 45 
to His/Pro/Thr 45 (Table 7, Figure 24 & Figure 25).  
Similarly, the majority of XCGD-SB54CW clones (26 out of 28) exhibited the wild type. 
However, two clones with single nucleotide deletions did not match the wild type 
sequence. (Table 7, Figure 24 & Figure 25). One clone has a R54G missense mutation 
and the other one hat A53P modification. 
In contrast, more than half of the ORFs reconstituting the XCGD-SB173CW mutation 
which resides in the 4th transmembrane domain of CYBB19, were non-canonical, 
including a 4-nt insertion, one 2-nt deletion, three 8-nt deletions and four 14-nt 
deletions(Table 7, Figure 24 & Figure 25). According to the SMART modular 
architecture research tool (http://smart.embl-heidelberg.de/), neither of these ORFs 
seriously affects the integrity of the transmembrane domain explaining why gene repair 
efficiency was highest in XCGD-173CW cells (Figure 22 & Table 8). 
 
 
 
 
 
Figure 23: FACS profile of sorted CYBB+XCGD cells 
  Results 
78 
 
Table 7: Types of indels recovered from sorted CYBB+ XCGD cells 
CYBB 
mutation 
# clones # indels # ORFs genotype protein 
SB45CW 41 28 26 -3 
G>T(22x) 
G>A 
G>C 
CG>AC 
K44del 
WT 
R45H 
R45P 
R45T 
SB54CW  30 29 28 -1(26x) 
-1 
-1 
WT 
R54G 
A53P 
SB173CW  28 23 21 +4 
+1(11x) 
-2 
-8(2x) 
-8 
-11 
-14(3x) 
-14 
173insR 
WT 
T173_L174delinsM 
L173-A175del 
L173-G176delinsS 
A170-L173del 
V171-A175del 
L173-I177del 
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Figure 24: Indel analyses of the shot-gun clones and single cells 
Indel sequences recovered by shot-gun cloning and single cell limited dilution clones from XCGD-
SB45CW, XCGD-SB54CW and XCGD-SB173CW cells. Note: Mutations out of the gRNA region were 
likely caused by PCR errors. 
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Figure 25: FACS analyses of the single cell clones form SB45CW, SB54CW and SB173CW 
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Table 8: Computational Transmembrane sequence analysis from XCGD-SB173CW single cell 
clones 
CYBB 
mutation 
genotype protein TM region TM protein sequence 
SB173CW +4 
+1(11x) 
-2 
-8(2x) 
-8 
-11 
-14(3x) 
-14 
173insR 
WT 
T173_L174delinsM 
L173-A175del 
L173-G176delinsS 
A170-L173del 
V171-A175del 
L173-I177del 
169 to 191 
168 to 190 
167 to 189 
167 to 189 
165 to 187 
165 to 187 
165 to 187 
165 to 187 
LAVTRLLAGITGVVITLCLILII 
YLAVTLLAGITGVVITLCLILII 
LYLAVMLAGITGVVITLCLILII 
GGLYLAV(A/T)GITGVVITLCLILII 
GGLYLAVTSITGVVITLCLILII 
GGLYLLAGITGVVITLCLILIIT 
GGLYLAGITGVVITLCLILIITS 
GGLYLAVTTGVVITLCLILIITS 
 
To test whether CYBB+ XCGD-54CW- and XCGD-173CW cells exhibit NADPH 
oxidase activity, sorted CYBB+ cells (Figure 23) were induced to differentiate by DMSO 
and the resulting granulocytes exposed to phorbol-12-myristate-13-acetate (PMA) 
(Figure 26). Superoxide production was measured by using dihydrorhodamine-123 
(DHR) reduction assay142. Figure 27 shows that CYBB corrected XCGD-54CW- and 
XCGD-173CW cells produced as much superoxide as the wild type CYBB expressing 
XCGD-SBwtCW cells. Moreover, as shown in Figure 27C the repaired cells expressed 
both non-glycosylated and glycosylated CYBB, in contrast to the untreated control cells 
where CYBB was undetectable. 
 
 
Figure 26: Differentiation of XCGD cells 
XCGD cells differentiation after exposure to DMSO. Cells were incubated for 7 days with DMSO (+), stained with 
anti-CD11b antibody and analyzed by FACS.  
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Interestingly, the clone SB173CW-C24 were get from limited dilution looks interesting, 
because it has 4 amino acid deletion. In silico analysis show, that the clone has 5 
difference in the transmembrane domain compare to wild type CYBB (Figure 28A). To 
analyze, if this subclone has the same functionally activity as the pool, the subclone 
and the XCGD-173CW pool were analyzed by DHR-assay. Therefore subclone and 
the XCGD-173CW pool were differentiated to analyze NADPH activity.  
 
 
 
 
 
Figure 27: NADPH oxidase activity in CYBB corrected XCGD cells 
A. Representative histograms depicting ROS production by differentiated, CYBB+ XCGD cells after 
stimulation with PMA. ROS levels were estimated by measuring the oxidative conversion of 
dihydrorhodamine123 into rhodamine123 which exhibits green fluorescence (DHR assay). B. Mean 
fluorescence intensity exhibited by differentiated XCGD cells before and after CYBB repair. XCGD 
and XCGD-SBwtCW cells served as negative and positive controls, respectively. C. Western blot 
showing CYBB protein expression in XCGD-SBwtCW control cells and in sorted BFP+ XCGD cells 
carrying the CYBB mutations after RGN-IDLV transduction. Results are represented as means ± SD 
of 2 independent experiments. ***p<0.001.  
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As shown in Figure 28, this clone were CYBB positive and the cells were Rho123-
positive, suggesting a strong oxidative burst. The Rho123 MFI of subclone was only 
slightly lower as the pool (Figure 27C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Functional analysis of the SB173CW-C24 clones 
A. In silico analysis of the transmembrane domain in the wild type and SB173CW-C24 CYBB protein. 
B. FACS data for SB173CW repair bulk and SB173CW-C24 clone. C. Rho123 MFI exhibited by 
differentiated XCGD cells as well as SB173CW repair bulk and SB173CW-C24 clone. 
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3.6 Estimating on target mutation efficiency at the endogenous 
CYBB locus in PLB cells   
Finally, to determine whether the NHEJ gene repair strategy would work with similar 
efficiency at the endogenous CYBB locus, wild type PLB cells were transduced with 
LCBFP-sgCYBB LVs in which the sgRNAs targeting the R54fs and L173fs mutations 
were replaced with sgRNAs targeting the corresponding wild type sequence (sgEx3 
and sgEx6; Figure 29. PLB cells transduced with LVs expressing scrambled (off target) 
sgRNA (LC-NTC) served as positive controls. When analyzed by flow cytometry, over 
75% of the LC-sgEx3- and LC-sgEx6-LV transduced cells ceased to express CYBB 
(Figure 29B) which was confirmed by Western blotting (Figure 29C). To directly 
estimate the on target mutation rate, several indels recovered by shot-gun cloning from 
LC-sgEx3- and LC-sgEx6-LV transduced cells were sequenced. As shown in Figure 
30, 21 out of 25 exons 3 and 19 out of 25 exons 6 exhibited a mutation, suggesting in 
full in agreement with the flow cytometry results an on target mutation rate of up to 
75% (84% for exon 3 and 76% for exon 6). This on target mutation rate should be 
sufficient to correct enough cells to protect X-CGD patients from microbial infection. 
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Figure 29: On target mutation efficiency at the endogenous exon 3 and exon 6 CYBB gene 
A. Schematic representation of the CYBB locus with gRNA target sequences. B. Flow cytometry analyses of 
the PLB985 cells targeted with LC-sgNTC, LC-sgEx3 or LC-sgEx6. C. Frequency of CYBB positive cells 
amongst after treatment, the sgNTC treated cells was set to 100%. D. Western blot showing CYBB protein 
expression. 
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Figure 30: Indel analyses of the shot-gun clones from endogenous CYBB locus 
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4. Discussion 
The focus of this work was to develop an RGN based strategy for in situ gene repair 
of point mutations causing monogenic blood disorders.  
 
Over 10.000 monogenic disorders are presently known of which more than 200 are 
primary immune deficiencies (PIDs)10. These inherited disorders are the result of a 
mutation afflicting only one gene (single gene disorder) within all cells of the body. To 
date the only curative treatment for patients with PID is HLA-matched allogeneic 
hematopoietic stem cell transplantation. The probability of finding a HLA-matched 
donor varies among racial and ethnic groups. Patient of European descent have the 
best chance of finding a matched donor (75%) whereas black patients of South or 
Central American descent have the worst probability of finding a matched donor 
(16%)30. For patients without a suitable HLA-matched donor, ex vivo gene therapy is 
the only alternative approach. 
 
In the last three decades over 2400 clinical gene therapy trials have been initiated 
(April 2017: http://www.abedia.com/wiley/phases.php). Most trials relied on the 
introduction of healthy gene copies into the diseased cells using a variety of vectors 
including adenovirus-, adeno-associated virus (AAV)-, γ-retrovirus-, lentivirus-, and 
Sleeping Beauty (SB) transposon vectors. Although most strategies proved effective 
in terms of gene replacement, but side effects such as insertional mutagenesis leading 
to clonal outgrowth and leukemia’s, combined with epigenetic silencing of the 
transgene and low engraftment rate limited their widespread use and stimulated the 
development of more advanced vectors with improved safety and efficacy profiles58,62. 
 
Due to these serious side effects caused by randomly integrating gene therapy vectors, 
novel strategies based on site-specific gene targeting and designer endonuclease 
mediated gene editing technologies are being pursued intensely. Accordingly, 
successful correction of human gene mutations by Zinc finger (ZFN) -, transcription 
activator like (TAL) - or by RNA guided (Cas9) endonuclease directed homology 
directed repair (HDR) in hematopoietic- and induced pluripotent stem cells has been 
reported for several inherited blood disorders including X-linked severe combined 
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immune deficiency (SCID)134,145, sickle cell anemia146,147, -thalassemia148,149 and 
most recently, chronic granulomatous disease (CGD)122,150. 
 
In this study, designer endonucleases were used to correct point-mutated transgenes 
in both murine and human hematopoietic cells. To test the suitability of this approach 
initial studies took advantage of the Hprt gene expressed in an endogenous locus in 
32D murine hematopoietic cell line. Despite being a “safe harbor” gene whose 
disruption has no functional consequences in hematopoietic cells, HPRT has the 
unique advantage of enabling negative and positive selection151. Thus, to test the 
efficacy of genome editing in hematopoietic cells, TAL-effector nucleases directed 
against the active center of Hprt were nucleofected into 32D cells together with a 
promoter-less, EGFP encoding targeting (donor) construct. After selection against Hprt 
expression, less than 5% of cells still expressed EGFP. This suggests that in the 
majority of the surviving cells (95%) the DSBs induced by the TAL-effector nucleases 
were repaired by NHEJ and only a minority (5%) by HDR (Figure 10). This was 
confirmed in single cell clones isolated by limiting dilution of which none underwent 
homologous recombination.   
 
These results are consistent with previous studies showing that DSBs repair by NHEJ 
vastly exceeds DSB repair by HDR in all stages of the cell cycle152,153. In contrast to 
NHEJ, HDR is nearly absent in G1 and exhibits its highest activity only during S 
phase152,153. Overall, this suggests that DSBs are preferentially repaired by NHEJ 
rather than by HDR (95% compared to only 5%). Even if the HDR strategy would be 
the ideal procedure to directly replace the diseased genes at their endogenous loci, 
due to the very low efficiency is HDR not suitable for gene therapy for monogenic 
disorders. However, NHEJ rather than HDR could be a more efficient approach to gene 
repair. 
 
Nevertheless, successful corrections of human disease mutations in hematopoietic- 
and induced pluripotent stem (IPS) cells by designer endonucleases have been 
reported that were exclusively based on HDR (see Table 5). In most of these 
applications, endonucleases and templates were delivered by nucleofection or 
electroporation of several plasmids, each expressing one of the functional components 
required for gene editing111,122,134,145,146,149,150. Because these procedures are highly 
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toxic154, only a small fraction of cells survive electroporation and even fewer retain all 
components required for successful genome editing. In addition to these technical 
considerations155, DSB repair by HDR is down regulated in quiescent HSC’s in favor 
of NHEJ156.These biological and technical factors reduce the number of cells with gene 
repaired by HDR and therefore most protocols rely on positive selection to enrich for 
gene-corrected cells122,146,147,149. Hence, for clinical applications, a more effective 
genome editing approach would seem quite useful. 
 
Initial clinical trials employing designer endonucleases involved AIDS patients126. In 
these trials ZFN were used to target and inactivate the CCR5 receptor in T-cells which 
is required for HIV infection. By generating DSBs within the CCR5 gene of T-cells via 
ZNF, the CCR5 gene was knocked out after introduction of indels by NHEJ and 
patients became resistant to HIV infection (clinicaltrials.gov; NCT00842634, 
NCT02500849)126. While these trials demonstrated that gene therapy based on NHEJ 
is a suitable approach, it remained unclear how many indels reconstituted the CCR5 
open reading frame (ORF). While this seems unimportant in the context of AIDS since 
T-cells with reconstituted CCR5 would automatically be selected against, the efficiency 
of gene repair by NHEJ is crucial for the success of a gene therapy of inherited blood 
disorders and this is exactly what the present study was designed for.  
 
In theory, approximately one third of the indels associated with NHEJ should restore 
the ORF disrupted by a disease mutation. This would lead to a significant number of 
ORF reconstitutions of which some, depending on the position and type of the original 
mutation, should either completely or partially recover protein function. This is 
supported by the in silico analysis (Figure 11) of indels showing the majority (77%) of 
ranges between15 nt deletions and 5 nt insertions (-15 nt to +5 nt). Assuming that one 
third of all indels reconstitute the reading frame of a mutated gene, approximately 25% 
of the targeted cells should re-express a completely or partially functional protein. 
Expression of a (partially) functional protein in 25% of the affected cells is sufficient for 
treatment of the most of the PIDs and a lot of other monogenic diseases.  
 
Proof of concept for gene correction by NHEJ has been recently obtained in patients 
with Duchenne’s Muscular Dystrophy (DMD)131,157. DMD is an X-linked inherited 
disorder caused by large intragenic deletions of one or more exons disrupting the 
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dystrophin ORF157. Dystrophin covers over 2.4 megabases contains 79 exons coding 
for 3,685 amino acid and is the largest human genes.  
 
Ousterout and colleagues131 could restore the ORF of the dystrophin gene in skeletal 
myoblasts of patients with exons 48-50 deletion (Δ48-51) resulting in a premature stop 
codon in exon 51. Using TALENs, they introduced indels into exon 51 and reconstituted 
the dystrophin gene in one clone. Using patients cells with the same mutation (Δ48-
50), Moggio et al.157 pursued an alternative strategy in addition to this indel strategy. 
They multiplexed two gRNAs (RGN-RGN) to remove the targeted exon 51 in patient-
derived muscle cells, thereby resetting the reading frame157. This exon-removing 
strategy157 works only for exons whose removal does not significantly interfere with 
protein function. Moreover, it is crucial that splicing into the adjacent downstream exon 
does not disrupt the ORF which has been observed to occur in rare cases. 
 
Unlike the dystrophin studies, the present work addressed the direct correction of point 
mutations by NHEJ. Initial experiments involving the Hprt locus in 32D hematopoietic 
cells confirmed that NHEJ directed DSB repair is significantly more effective than HDR. 
Accordingly, 95% of TAL nuclease expressing cells obtained after negative selection 
(6-TG) harbored indels in the active center of HPRT (Figure 10). Moreover, exposure 
of a 6-TG resistant subclone with an indel-induced Hprt-inactivating frameshift 
mutation to a second round of TALEN-directed DSB repair yielded HAT-resistant cells 
derived from two independent clones - one with a synonymous substitution restoring 
the Ala50 codon and one with an Arg51 to Gly51 codon conversion that only partially 
inactivates HPRT (Figure 12). In human pathology this mutation is associated with the 
Kelley-Seegmiller Syndrome158. Affected patients develop urinary tract stones and mild 
neurological symptoms. Because this targeted mutation was in the active center of 
HPRT, not many modifications were accepted. For mutations located in other areas 
not as important to protein function, NHEJ repair will presumably accept more changes 
such as deletions or insertions of amino acids and thus be more efficient. 
 
Overall, these results confirm that in situ gene repair by designer endonucleases does 
neither require donor templates nor the restoration of the original wild type sequence. 
However, these experiments have so far yield no information about the repair 
efficiency. To determine the efficiency of gene repair by NHEJ, a simple experiment 
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that does not require a selection and has no positive or negative effect on cell growth 
is sufficient. A fluorescent protein with the point mutation would be ideal for gene repair 
by NHEJ. 32D cells expressing EGFP from the Hprt locus after HPRT-TALEN and 
EGFP donor treatment (32D-EGFP+) were enriched and subjected to CRISPR/Cas9 
mutagenesis using two different sgRNAs directed against the N-terminus of EGFP 
(Figure 13). Here, TALENs were abandoned after publication of CRISPR/Cas9-based 
gene editing. The reason to switch of strategy from TALEN to CRISPR/Cas9 system 
was the generally poorer efficiency of TALENs and the fact that TALENs cannot cut 
methylated DNA105,159. CRISPR/Cas9 system is easier to design and to clone, is more 
cost and time-effective, usually has a high efficiency and the endonuclease can cut 
inside both methylated and non-methylated DNA105.  
 
Four subclones (Figure 14) with defined frameshift mutations were isolated from the 
mutant pools (Figure 15). T Subclones were chosen by first taking two subclones from 
each of the used sgRNA and second by selecting two subclones with the insertions 
and two with the deletions of one or two nucleotides. The clones were then 
nucleofected with dedicated RGNs together with Cas9 vector (two plasmid system). 
Gene repair efficiencies were low ranging from 2 - 5% (Figure 15) which reflected the 
overall toxicity of the electroporation gene delivery approach154. The sequences of 
corrected functional EGFP shows that in the most of the cases, the EGFP ORF was 
restored to its original sequence by either frame-shifting the nucleotide deletions or by 
frame-reconstituting nucleotide insertions. However, this experiment showed that the 
gene repair efficiency by NHEJ without any selection can be as high as the one in the 
case of HDR (Figure 10) with selection. Additionally, NHEJ doesn’t need any selection, 
meaning that it doesn’t require long incubation times of HSC in clinical applications. 
This would probably lead to an efficient transplantation of the HSC, which undergo less 
differentiation in vitro.  
 
The next line of research focused on adopting these processes to human cells. PLB985 
human acute myeloid leukemia cell line is well-suited for this purpose, because 
different gene therapy approaches have demonstrated that this cell line is a powerful 
tool for functional analysis of the NADPH oxidase complex. Additionally, a knock-out 
CYBB model of this cell line (XCGD-PLB985 cell line) mimics a natural mutation 
occurring in the X-linked Chronic Granulomatous Disease(X-CGD)142,144,160. In the first 
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experiment, PLB leukemia cells with one copy of a mutant EGFP reporter inserted into 
their genome were used to test the NHEJ approach in human cells. Using template 
free RGNs delivered by integrase-defective lentiviruses (IDLVs), on-target mutation 
rates approaching 100% were obtained (Figure 18 & Figure 19). Combined with the 
achieved gene repair efficiency of 27% (Figure 18, section 3.4), the result suggests 
that about one in four NHEJ events reconstituted EGFP function. This repair efficiency 
exceeded the EGFP repair efficiency in 32D cells by almost 5- to 10-fold. The majority 
of these effects can be attributed to the IDLV–RGN delivery approach. This system, 
unlike the two plasmid system employed by nucleofection, delivers all components 
required for gene editing within one vector by cell infection, - an approach generally 
less toxic than electroporation. Unlike IDLVs which engage cell surface receptors for 
cell entry, electroporation requires cell permeabilization leading to cell content leaks 
adversely affecting adjacent cells. Moreover, electroporation generates random DSBs 
that can cause mutations161,162. Additionally, transfected donor DNA after inserting can 
integrate randomly into the genome after insertion. IDLVs express the RGNs 
episomally from one or two LTR circles which are diluted out by cell replication ensuring 
transient expression and preventing insertional mutagenesis163–167 – a major safety 
issue in clinical trials employing integrating lentiviruses. Although between 0.35 and 
2.3% of IDLVs can still integrate into the genome, depending on the IN mutation and 
vector dose165,168 the probability of long term adverse effects is rather low because 
constitutive Cas9 expression activates the immune system leading to elimination of 
Cas9 expressing cells169. Remaining safety concerns with IDLVs could be addressed 
by inserting suicide genes such as the herpes simplex virus thymidine kinase (HSV-tk) 
gene enabling the elimination of HSV-tk expressing cells in vivo by administering the 
pro-drug as ganciclovir170,171. 
 
Analysis of the reconstituted open reading frames (ORFs) showed that all modification 
with single amino acid deletions were compatible with EGFP fluorescence (Figure 19). 
This is consistent with recent reporting showing that loss of amino acids from the N-
terminal α-helix of GFP negatively interfere with EGFP fluorescence172. Interestingly, 
analysis of the reconstituted open reading frames (ORFs) showed that all but single 
amino acid deletions were compatible with EGFP fluorescence. More specifically, the 
short hydrophobic N-terminal α-helix of EGFP stabilizes its barrel structure which is 
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required for fluorescence and therefore only small hydrophobic amino acids, such as 
alanine are tolerated at this site172 
 
Next, the template free IDLV-RGN strategy was tested on a real monogenic diseases. 
For this purpose, X-linked chronic granulomatous disease (X-CGD) were selected. As 
already described, there exists a cell line CYBB knock-out (KO) model for X-CGD 
(XCGD-PLB985) and after knock-in (KI) of the CYBB gene, XCGD-PLB985 cells are a 
powerful tool for functional analysis of the NADPH oxidase complex. Importantly, 
neither the KO nor the KI has any effect on cell growth15. If the cells with KO or KI had 
a proliferation advantage, experiments assessing on-target gene editing efficiency 
would yield biased data. 
 
To test the RGN strategy on bona fide disease genes, several patient specific CYBB 
mutations causing X-CGD were selected from the Immunodeficiency mutation 
databases (CYBBbase variation browser; http://structure.bmc.lu.se/idbase/ 
CYBBbase), including two frameshift-, one missense- and one nonsense mutation. In 
vitro models for X-CGD were obtained by introducing the mutations as CYBB 
transgenes into CYBB-KO PLB cells (XCGD-PLB985)144. As promyelocytic leukemia 
cells expressing the NADPH oxidase complex, PLB cells were perfectly suited for 
testing the RGN approach15. Treatment of the respective mutations with dedicated 
RGNs showed that up to 10% of the transduced XCGD cells harbouring CYBB 
frameshift mutations recovered CYBB expression and produced superoxide anions 
after differentiation into granulocytes. Considering the estimated on-target mutation 
rates of 30% and 26% in XCGD-SB54CW- and XCGD-SB173C cells, respectively 
(Figure 22) the actual frequency of gene repairing NHEJ events is estimated to be 27% 
for the SB54CW - and 38% for the SB173CW mutation (Table 9).  
 
In comparison, both nonsense and missense CYBB mutations showed reduced on-
target mutation rates (Figure 22) which may be due in part to the low CG content of 
the respective sgRNAs (Table 9)173. Moreover, as Cas9 has been shown to tolerate 
single nucleotide mismatches174, selection against single nucleotide substitutions by 
RGN retargeting of already corrected templates may reduce repair efficiency even 
further. 
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Table 9: Theoretical frequency of gene repair 
Mutation Mutation type On target 
[%] 
Repair 
[%] 
Theoretical 
repair efficiency 
by 100% on 
target [%] 
GC content  
SB54CW frameshift 
(duplication ) 
29.6 8.0 27.0 68 
SB173CW frameshift 
(deletion) 
25.7 10.3 40.1 58 
SB45CW missense 16.7 1.8 10.8 32 
SB124CW nonsense 16.2 0.8 4.9 21 
Theoretical repair efficiency = Repair ∗
100
On Target
 
 
However, considering that residual NADPH oxidase activity at 5 - 10% of normal levels 
is already sufficient to protect X-CGD patients from microbial infections20,175 and that 
even residual activity of 1 - 2% of normal level provides a significant survival 
benefit175,176, even the low repair rates of missense and nonsense mutations would 
suffice if RGN transduction rates approached 100% (Table 9). In addition, the reported 
on target mutation rates are likely an underestimate because the sensitivity of the 
employed classic surveyor assay is limited177. In some cases the real mutation rate 
could be 20% higher than that measured by surveyor assay. 
 
Notwithstanding the above considerations, repair rates are also contingent on the 
respective targeted mutation sites. Whereas the SB45CW mutation is located within a 
splice site of exon 2178 and required reconstitution of the wild type ORF. The SB54CW 
mutation is located in the redox active center of CYBB81,179–181 almost exclusively 
required wild type ORF reconstitution, too. In contrast, the SB173CW mutation located 
in the fourth transmembrane domain also tolerated a variety of non-canonical ORFs 
(Table 7 & Figure 24 & Figure 25). According to the SMART modular architecture 
research tool (http://smart.embl-heidelberg.de/), neither of these ORFs seriously 
affects the integrity of the transmembrane domain, thus explaining why the gene repair 
efficiency was highest in XCGD-173CW cells. 
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To determine whether the NHEJ gene repair strategy would be similarly efficient at the 
endogenous locus, wild type PLB cells were treated with RGNs targeting the exons 
harbouring the R54fs and L173fs mutations. In both cases, the KO analysis of CYBB 
by flow cytometry and western blot (Figure 29) shows KO efficiency above 75% and 
the on target mutation rate determined by sequencing of indels recovered by shot gun 
cloning was also above 75%. Assuming gene repair efficiencies of about a quarter 
(Figure 18), this data imply an in situ gene repair efficiency of at least 20%, which is 
sufficient to protect X-CGD patients from microbial infection and thereby prevent the 
major cause of death in X-CGD. 
 
The next step to continue this work would have been final validation of the outlined 
strategy in primary X-CGD patient cells, but it was not possible to obtain suitable 
primary material. X-CGD is a rare disorder and most patients are severely ill, rendering 
access to primary material by bone marrow aspiration or apheresis following HSPC 
mobilization by G-CSF very challenging. Bone marrow aspiration is painful, complex 
and carries the risk of both patient infections and contamination of material. Apheresis 
is easier, but HSPC must be mobilized with recombinant granulocyte colony-
stimulating factor (G-CSF), which can have side effects such as severe bone pains, 
headache, arthralgia, malaise, fatigue, insomnia nausea182. A suitable and consenting 
donor could not be found in the available time, and therefore an IDLV-RGN repair in 
primary human HSPCs could not be demonstrated here. 
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5. Conclusions and Outlook  
The present work has provided proof of concept for site directed gene repair by NHEJ 
in an X-CGD model.  
 
The data shown provide evidence for high efficiency gene repair by donor template 
free CRISPR/Cas9 technology using transient, IDLV based RGN transduction into 
hematopoietic cells. Unlike the widely adopted gene repair by homologous 
recombination (HDR), gene repair by NHEJ requires no donor templates, and is 
significantly more efficient because unlike HDR, operates in all phases of the cell cycle. 
Furthermore, NHEJ is the dominant DSB-repair pathway in quiescent (G0) 
HSCs153,155,156, which are the desired target cells for gene therapy of most monogenic 
blood disorders. Procedurally, the single vector IDLV-RGN delivery made possible by 
a template-free CRISPR/Cas9 approach is one of its most attractive technical features, 
because it is transient, more efficient and less toxic than plasmid-based technologies. 
Thus, gene therapy based on the template free IDLV-RGNs provides a sensible 
alternative to existing gene therapy protocols. The present study has shown that 
frameshift mutations can be effectively repaired in hematopoietic cells by donor 
template free CRISPR/Cas9 gene editing 
 
According to the CYBBbase database183, 24% of all X-CGD patients harbor CYBB 
frameshift mutations. This frequency is similar to the frequency of frameshift mutations 
found in the IL2R184,185, WASP186,187, ADA188, and HBB189,190 genes of patients with 
X-linked immunodeficiency disease (X-SCID), Wiskott-Aldrich Syndrome, 
adenosinedeaminase immunodeficiency disease (ADA-SCID) and -thalassemia, 
respectively. Thus, at least one in four to five of these patients could benefit from gene 
therapy with donor template free, RNA-guided Cas9 endonucleases. For most of these 
genes, recover of less than 10% of wild type protein activity is already sufficient for 
obtaining a therapeutic effect. For immunodeficiency diseases in which positive 
selection occurs (e.g. X-SCID, ADA-SCID, WAS), even lower gene repair rates are 
sufficient because repaired cells will overgrow diseased cells over time after 
transplantation.   
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However, before reaching clinical maturity the strategy needs to be validated in vivo. 
For this, transgenic mice carrying humanized and patient-specific X-CGD or X-SCID 
mutations produced by single embryo CRISPR/Cas9 gene editing191 will be used for 
syngeneic bone marrow transplantation experiments in which ex vivo repaired 
hematopoietic stem cells are injected into lethally irradiated recipients followed by long 
term disease and gene expression monitoring. Special attention will be paid to potential 
adverse effects caused by off-target mutations detected by dedicated reporter assays 
and whole genome sequencing which will also reveal possible IDLV genome 
integrations.  
 
In a second preclinical approach which is largely dependent on patient availability (see 
Discussion), hematopoietic stem and progenitor cells (HSPCs) recovered from the 
peripheral blood after G-CSF mobilization will be transplanted after ex vivo gene repair 
into immunodeficient NSG mice150. Successful gene repair rates and off-target effects 
will then be monitored by standard methodology.  
 
Ideally, RGN delivery for gene therapy should be transient and virus free to avoid 
insertional mutagenesis and immunological side effects. Therefore, special 
consideration should be given to alternative RGN delivery strategies, in the future 
experiments. Most promising in this regard are advanced electroporation strategies 
delivering the RGNs as preassembled gRNA/Cas9 protein complexes192,193. 
 
Finally, the donor template free CRISPR/Cas9 approach should be easily adaptable to 
non-SCID diseases such as Haemophilia or Duchenne Muscular Dystrophy. 
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